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Abstract 
Improvement of a commercial probiotic product through metabolite profiling 
and quality assurance system development 
by 
Nagaiah Koneswaran  
In recent years, use of probiotic formulation for animal health and nutrition has gained popularity to 
produce high quality animal based food products i.e. milk and meat. As a result, number of probiotic 
products in the market has increased. However, there is an increasing concern about the quality and 
safety of these products and the importance of ensuring quality control of the probiotics has widely 
been accepted. BioBrew Ltd produces liquid animal probiotics widely administered to the farm 
animals in New Zealand. In this study more than 300 samples at various stages of production were 
analysed. Sampling across New Zealand was carried out for a period of eight months (August 2013 to 
March 2014). BioBrew Animal Nutritional supplement (BBAN) is molasses fermented liquid 
formulation having multi-species of Lactic Acid Bacteria (LAB) and yeast cells.  
Viability study was undertaken to enumerate LAB and yeast cell counts in BBAN using traditional 
plate count methods. Production involved three stages fermentation and viable LAB cell counts in 
stage 1, 2 and 3 differed significantly (P < 0.05). However, viable counts in stage 3 and final product 
with different storage days did not differ significantly (P < 0.05) and cell densities on average were 
found to be more than 109 CFU/ml in the product, which was higher than Minimum Suggested Level 
(MSL). On contrary, average yeast cell densities reached maximum in stage 1 and 2 (9.97 and 10.24 
log CFU/ml respectively) dropped to 5.47 log CFU/ml at the end of storage period. On average, yeast 
cell counts in the product were just below the MSL, irrespective of product from different production 
sites.  
Analysis confirmed that the product contained considerable amount of lactic acid and ethanol in 
BBAN. Headspace Solid-Phase Micro-Extraction Gas Chromatograph Mass Spectrometry (HS-
SPME/GCMS) analysis was used to detect the semi-volatile and volatile metabolites in this probiotic 
formulation. Lactic acid, ethanol and butyric acid were primary metabolites detected in higher 
quantities in BBAN formulation. Lactic acid, acetic acid, ethanol, butyric acid, diacetyl were the 
important metabolites identified with antimicrobial properties. 
ii 
Products were screened for potential foodborne pathogens and confirmed BBAN formulation were 
not detected positive for the presence of any bacterial pathogens over the period of study. However, 
contamination with yeast (Rhodotorula rubra) observed in 2 batches during the period of study. 
Favourable conditions for this detected yeast contamination were identified and were effectively 
controlled through measures suggested in this study. 
Based on our study, model quality assurance (QA) system was proposed to produce consistent, high 
quality and safe BBAN. Model QA system includes products testing for pH, temperature, viable 
counts, safety assessment and presence of metabolites at different stages as well as during various 
storage days.  
In summary, it was confirmed that BBAN met the quality control parameters. BBAN has lactic acid, 
butyric acid, ethanol, acetic acid and diacetyl as major bioactive compounds. BBAN batches tested 
were free from pathogenic contamination. This study suggested a model QA system to enhance 
quality and safety of the product. 
 
Keywords: probiotics, BioBrew, BBAN, viable counts, colony forming unit (CFU), metabolite profiling, 
GCMS, SPME, metabolic compounds, chromatogram, internal standard, relative amount, pathogen, 
quality assurance (QA). 
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Chapter 1 
Introduction 
Demand for safe and high quality food of animal origin has increased, especially after recent 
outbreaks of foodborne diseases and food poisoning scandals (Hussain & Dawson, 2013).  Zoonotic 
diseases are transmitted from animal-based food to humans. Antibiotics at low doses/sub-
therapeutic levels have been used as growth promoters in animal feeds and to improve the quality 
of animal meat with a lower percentage of fat and higher protein content. The control of zoonotic 
pathogens such as Salmonella, Campylobacter, Escherichia coli and Enterococci is perceived to be 
another benefit of these antibiotic growth promoters (AGP) (Cogliani et al., 2011). However, the use 
of antibiotic as AGP in livestock was banned due to worldwide concern about the development of 
antibiotic resistance in humans (Castanon, 2007). The ban on use of AGP has been a challenge for 
animal nutrition and health increasing the need for alternative methods to improve animal 
production and control or/and prevent pathogenic bacteria.  
In this context, the use of probiotics has been put forward to be used as a best practice alternative 
to AGP and much research has been done to substantiate the beneficial effects of probiotics such as 
improvement of gut microbial balance and acting against gut pathogens in animals. Probiotic use in 
agriculture started several decades ago (Fuller, 1999) and today hundreds of animal probiotic 
products are available in the global marketplace. However, there is an increasing concern about the 
quality and safety of these products and the importance of ensuring quality control of the probiotics 
has widely been accepted. 
Quality-control properties must be continuously controlled and optimized and these properties can 
be evaluated in two steps. i.e., quality analysis before and after administration of these products. 
Properties before administration may include viability and survival throughout the manufacturing 
process, safety of product and metabolite profiling, etc. On the other hand quality parameters after 
administration may include bile and acid stability, colonization properties, immunogenicity, adhesive 
properties, etc. Most of these quality control properties are related to the selection criteria of 
probiotic strains, but probiotic properties may be influenced by long-term industrial processing and 
storage conditions. Thus, in addition to technological properties, functional properties should be 
considered in quality-control measures (Tuomola  et al., 2001).  
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Viability is regarded as most important quality assurance parameter (Tuomola  et al., 2001). 
Probiotic microorganisms have to encounter a series of stress conditions during processing and very 
low pH and detergent like bile salt when it travels through the gastrointestinal tract (GIT). These 
conditions seriously challenge the viability of probiotic microbes. Therefore, it is important to 
measure the viability of the probiotic products as claimed by the producers. It has been reported 
that the number of probiotic microbes found in certain products were below what was declared or 
they were altogether absent (Wannaprasat et al., 2009). Although health benefits from probiotic use 
depend on number of viable counts present in the product, it also varies with target animal and 
probiotic species used. MSL of probiotic viable counts in product is 106 CFU/ml (Adhikari  et al., 2003; 
Vandenbergh, 1993). However, viable counts range 106-108 CFU/ml is expected to be efficacious, 
although the recommended dose in some countries is even higher than this level. For example the 
recommended viable counts of probiotics in Canada is 109 CFU/dose (CFIA, 2009). 
A number of quality analysis studies of probiotics in various countries have been involved for the 
samples collected from the market shelf (Table 1.1). 
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Table 1.1   Quality testing of the probiotics in different countries. 
Country Quality testing Reference 
Belgium 213 products were studied and most of the products 
had wrong label information (mislabelling). 
(Huys et al., 2006) 
Canada Two out of 25 tested animal probiotics were in good 
quality, rest of them had low viable numbers, 
misspelling of bacteria and lack of information about 
the contents. 
(Weese & Martin, 2011) 
China 28 probiotic product tested. Inconsistent Bacterial 
counts of specific species with the labelling, missing 
strain and wrong labelling. 
(Chen et al., 2014) 
Europe Half of the tested products had fewer lactobacilli 
than claimed and mislabelling with respect to the 
bacterial species also reported. 
(Coeuret et al., 2004) 
New Zealand Of 9 probiotics, all had at least the label viable cell 
numbers. 
(Olivier et al., 2008) 
New Zealand Three out of four probiotic feed supplements had 
very poor viable cell numbers.  
(Bennett et al., 2013) 
Nigeria Yoghurt tested for quality testing did not give 
adequate information about the product and 
product found to be contaminated with Escherichia 
coli, moulds and Bacillus. 
(Ifeanyi, 2013)  
Taiwan 
 
Of tested solid and liquid probiotics, solid product 
did not have viable LAB and incorrect labelling on 
the package. 
(Lin et al., 2006) 
Thailand Of 13 probiotics tested, all products had inaccurate 
labelling, misnaming and inaccurate viable cell 
numbers or species.   
(Wannaprasat et al., 2009) 
USA 58 commercial yoghurt were tested for quality 
testing most of the products contain viable strains 
below the level declared on the labels. 
(Ibrahim & Carr, 2006) 
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Products are examined for viable probiotic counts, presence of pathogens or metabolites etc. Based 
on the information provided on the label of the product, test results are compared with content of 
the product. However, very few or none of the studies have been reported with a continuous quality 
analysis for the probiotic with each stage of production and with continuous evaluation of quality 
analysis until its expiry date. 
Production of metabolic compounds by probiotics play a major role in controlling pathogenic and 
spoilage bacteria and some compounds exhibit anti-inflammatory effects. LAB produce a wide range 
of antibacterial such as organic acids (e.g., lactic acid and acetic acid, proteinaceous compounds 
(bacteriocins), antifungal peptides/proteins, low molecular mass peptides and other compounds 
such as reuterin and reutericyclin (Lefteris et al., 2006). Yeast acidifies the growth medium and 
tolerates high concentrations of ethanol. Production of antimicrobial compounds such as antifungal 
killer toxins or “mycocins” and antibacterial compounds demonstrate antagonistic activities toward 
undesirable bacteria and fungi in the probiotic products (Hatoum et al., 2012). Production of 
antimicrobial substances has been considered as one of several important probiotic mechanisms and 
a great deal of research focuses on the production of antimicrobial substances (Adhikari  et al., 
2003). 
Probiotics are fermented products and usually considered safe from pathogens or food spoilers  
because of the low pH and production of antimicrobial substances (Vinderola et al., 2000). However, 
the use of probiotic products are associated with three types of hypothetical safety issues. Those 
include occurrence of diseases, antibiotic gene transfer in the GIT and toxic metabolites secreted by 
probiotic microbes (Snydman, 2008). Furthermore, the observations of reported post-production 
contamination in the probiotics (Ifeanyi, 2013) emphasizes the need for evaluating the product for 
potential pathogens in the product.  
BioBrew Ltd produces fresh, living brews which are specialised microbial products for the 
agricultural sector. BBAN is a liquid probiotic widely administered to the farm animals in New 
Zealand. The aim of this MSc project is to develop scientific knowledge to produce a consistent 
quality commercial probiotic product for use in animal production. The ultimate goal is to design 
quality assurance system for production process. In general, sampling of probiotics at a given time 
from the market place has been used for quality control studies. However, we adopted a unique 
approach in this study and we consider quality control properties at many stages of production, 
storage stability through to the expiration of the product shelf-life. 
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This master’s research has the following specific objectives: 
• To identify the product characteristics which are responsible for its already demonstrated 
efficacy (metabolite profiling) 
• To assess the viability of probiotic microbes throughout production and storage 
(microbiological quality testing) 
• To develop a QA system to produce safe and high quality product 
• Strategies to enhance product safety and stability (shelf- life and safety) 
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Chapter 2 
Literature review 
2.1 Probiotics and their characteristics 
Probiotics are defined as “live microorganisms that are administered in order to provide a health 
benefit on the host” (FAO/WHO, 2001). The use of probiotics has gained interest as a natural way to 
improve health of both humans and animals. The global market for probiotic products was 
estimated at USD 24.23 billion in 2011 and expected to reach USD 44.9 billion in 2018. Application 
and demand for probiotic products have been increasing over the years and more than 500 probiotic 
products have been introduced in the past decade (Research and Markets, 2013).  
Probiotic microbes help to prevent gastrointestinal disorders and improve and maintain a well-
balanced intestinal flora (Lavermicocca, 2006). Well-investigated and documented  health benefits 
include increasing natural resistance to infectious diseases in the GIT, improving lactose intolerance, 
suppressing traveller’s diarrhoea and reducing bloating (Liong, 2007). Probiotic foods for human 
consumption have been marketed in Japan since 1920 (Svensson, 1999). 
 In order to achieve desired health effects the selection of suitable microbial strains plays a vital role. 
Selection criteria include bio-safety of the strains, origin of the strains, resistance to in vivo/vitro 
conditions, adherence and colonization ability to the intestinal epithelium, antimicrobial activity 
against enteric pathogens, viability or survival rate and resistance during processing and passage 
through the GIT (Kosin & Rakshit, 2006). Generally bacteria have been used in probiotic products. 
Fungi/yeast has also been used to a lesser extent. Bacteria used in the probiotics include 
Lactobacillus, Bifidobacterium, Bacillus, Enterococcus, Pediococcus, Streptococcus and Clostridium 
species whereas fungal or yeast probiotics include Saccharomyces cerevisiae, Saccharomyces 
boulardii and Aspergillus oryzae species (Canani et al., 2011; Cutting, 2011; Gueimonde et al., 2009). 
Depending on requirements, probiotic preparations may be mono-strain or multi-strain products. 
However, multi strain probiotic products, through synergistic adhesion effects, could act as broad 
spectrum protection against pathogenic infection in different host animals (Collado et al., 2007; 
Timmerman, 2004). Prebiotics are non-digestible oligosaccharides which act as carrier for probiotic 
microbes. Combined administration of probiotics and prebiotics are called synbiotics which provide 
definite health benefits through their synergistic action (Harish & Varghese, 2006). 
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2.2 Mechanism of action of probiotic microbes 
In order to provide health benefits probiotic microbes exert different mechanisms of action in 
animals. The modes of actions are as follows: 
(1) Alteration of intestinal microflora:  
Food/feed supplements containing probiotics have been demonstrated to alter the existing 
intestinal microflora so as to give benefits to the host. Probiotics maintain the balance and 
multiplication of beneficial microbial populations in the GIT resulting in the prevention and combat 
of digestive disorders (Corcionivoschi et al., 2010). 
(2) Immunomodulation of the host animal:  
Probiotics have the ability to shape the immune system of the host animal through physiological 
action in the intestines (Isolauri et al., 2001). A study demonstrated the Bacillus cereus var.toyoi 
altered the immune status and functionalities of systemic immune cell populations in piglets 
(Schierack et al., 2007). 
(3) Competitive exclusion (CE):  
Nurmi and Rantala (1973) found that administration of gut contents prepared from healthy adult 
chickens protected newly hatched chicks from Salmonella colonization of the gut. Probiotic bacteria 
eliminate pathogenic bacteria by different CE techniques which include competition for physical 
attachment sites, direct and indirect competition for nutrients, enhancement of host immune 
system, and production of antimicrobial substances (Callaway et al., 2008). 
 (4) Production of inhibitory substances by probiotics against pathogenic microbes:  
Probiotic microbes secrete bioactive compounds/metabolites which act against pathogenic 
organisms found in the gut. Metabolites produced by LAB include lactic acid, formic acid, acetic acid, 
propionic acid, benzoic, and phenyllactic acids. These metabolites play an important role in inhibiting 
pathogenic bacteria (Tharmaraj  & Shah 2009). 
2.3 Animal probiotics 
The primary goal of livestock production is the delivery of safe, reliable and high-quality foods for 
human consumption. Recent outbreaks of food-borne diseases stress the need for reducing bacterial 
pathogens in foods of animal origin. Foodborne pathogens such as Salmonella and Campylobacter 
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are transmitted along the food chain and can be the source of human illness (Santini et al., 2010). In 
the past, antibiotics have been added to animal feeds at sub-therapeutic levels to act as growth 
promoters (Dibner & Richards, 2005). However, the European Union banned the use of antibiotics as 
growth promoters in 2006 due to the worldwide concern about development of antimicrobial 
resistance and transference of antibiotic resistance genes from animal to human microbiota 
(Castanon, 2007). This resulted in an increased demand for viable alternatives that could enhance 
the natural defence mechanisms of animals and reduce the use of antibiotics (Verstegen & Williams, 
2002).  
In this context, the wider use of probiotic formulations has become popular using live microbial 
cultures to feed various animals as a substitute for the production-enhancing antibiotics. The use of 
probiotics to improve productivity in livestock is currently generating a great deal of interest.  
Animal probiotics are live microbial feed supplements that enhance performance and/or improve 
intestinal microbial balance of host animals (Fuller, 1989). The strong demand by consumers for high 
quality and safe foods of animal origin have consolidated the use of probiotics in animal nutrition as 
a way to raise healthy animals without chemical interaction, and thus to produce foods of reliable 
quality and safety. Probiotics in animal nutrition can confer improved resistance to pathogenic 
bacterial colonization, enhancing host mucosa immunity which reduce pathogen load and improve 
health status of the animals (Choct, 2009). 
2.4 Application of probiotics in animal farming 
2.4.1 Animal production/nutrition 
Application of probiotics in animal feed has dual purposes associated with animal production and 
animal health. Probiotic microbes have the ability to modulate gut microflora and probiotic strains 
separately and in combination can improve feed conversion rate, feed intake, daily weight gain and 
total body weight in farm animals (Torres-Rodriguez et al., 2007). The development of the probiotic 
approach to animal health started rapidly after the discovery of successful protection against 
Salmonella colonisation in newly hatched chicks by administering the gut suspension of healthy 
adult chickens (Nurmi & Rantala, 1973). 
Bacterial probiotics have been effective in pigs, chickens and pre-ruminant calves whereas yeasts 
and fungal probiotics such as S. cerevisiae, S. boulardii and A. oryzae have delivered results in adult 
ruminants (Fuller, 1999). Several studies have shown the supplementation of animals feed with 
probiotics has significantly increased meat, milk and egg production. For example, probiotic products 
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containing S. cerevisiae and A. oryzae have increased the milk production and milk solids-non-fats 
and tended to increase milk protein percentage in dairy cows (Yu et al., 1997). 
2.4.2 Animal health 
The gut microbiota is a complex natural resource that can be manipulated to reduce the impact of 
pathogenic microbes that affect animal production and the safety of food products. Animal feeds 
that are classified as probiotics, prebiotics and competitive exclusion cultures have been utilized as 
pathogen reduction strategies in animals that are used for food production with varying degrees of 
success. The use of probiotic and prebiotics aims to eliminate the foodborne pathogens that affect 
animal production or food safety (Callaway et al., 2008). 
 Farm animals subjected to environmental and management stresses can experience disturbances in 
the intestinal microbiota, which may favour pathogenic infection. Administration of probiotic 
mixtures (S. boulardii, B. subtilis H4 and LAB) in weaned piglets reduced E. coli counts in the 
intestine, lowered the incidence of diarrhoea, and increased production of lactic acid and volatile 
fatty acid concentration (Giang et al., 2010). Probiotic microbes such as Bifidobacterium lactis and 
Lb. rhamnosus reduced adherence of E. coli, Salmonella, and Clostridium species to the intestinal 
mucosa in swine (Collado et al., 2007).  Baum et al. (2002) showed that the administration of live 
yeast ( S. cerevisiae spp. boulardi) to weaned pigs for 3-4 weeks improved growth performance, 
villus height, epithelial cell proliferation and the number of macrophages at various sites of the small 
intestine. A similar study conducted by Bontempo et al. (2006), demonstrated that dieteray 
supplementation with S. boulardi prevented gastrointestinal disorders and promoted intestinal 
health in weaned piglets. 
Each year an estimated 1.4 million people had Salmonella contamination resulting in 400 deaths in 
USA (Voetsch et al., 2004). Probiotics are used in poultry to prevent and combat digestive disorders. 
For example, when oral Lactobacillus live culture (106 and 108 CFU/ml) administered to chicks 
infected with S. enteritidis, it resulted in a significant decrease of these pathogens (Higgins et al., 
2008). Campylobacteriosis is a zoonotic disease caused by Campylobacter jejuni. Poultry meat is 
main source of this disease and occurrence of this disease in human has been increasing in recent 
years in the European Union (Hugas et al., 2009). Probiotic strain Bifidobacterium longum PCB 133 
has shown an anti-campylobacter activity and campylobacteriosis in humans can be reduced by 
incorporating this probiotic strain as feed additive in poultry nutrition (Santini et al., 2010).  
Digestive disorders (diarrhoea) are the leading cause of morbidity and mortality in new born calves. 
Faecal shedding of E. coli O157:H7 in cattle is directly relevant to levels of carcass contamination 
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(Elder et al., 2000). Administration of a Lb. acidophilus culture was effective in reducing E. coli 
O157:H7 shedding by more than 50% in finishing cattle and isolation from the hides of the cattle by 
up to 75% (Brashears et al., 2003; Younts-Dahl et al., 2004). Yeasts as probiotics have been used in 
cattle to improve health and as a dietary supplement to influence animal performance. S. cerevisiae 
as a probiotic feed supplement was found to be responsible for increased food intake, increased 
milk production and increased body weight in ruminants (Corcionivoschi et al., 2010). 
2.5 Characteristics of animal probiotics products 
2.5.1 Viability of probiotic organisms 
Before a probiotic microorganism can start its biological role, it has to survive a series of stresses 
imposed during feed processing and passage through the GIT. Viability and stability of the probiotic 
products therefore have been both a technological and a marketing challenge for industry. Probiotic 
animal feeds should have probiotic strains and maintain the appropriate viable cell count during 
processing of the product and its entire shelf life. The present target of any probiotic food product in 
terms of viable cell numbers should be at least 106-107 CFU/ml at the end of its shelf life (Corcoran et 
al., 2006). Though different countries’ specific requirements vary depending on products, many 
studies have indicated the viability claims by the producers have shown low populations of the 
probiotic bacteria in the probiotic product (Shah et al., 1995). Maintaining the viability of the 
probiotic cultures in functional foods during processing is the major challenge for the food/feed 
industry. Processes involving drying are often needed in order to keep the food/feed for prolonged 
storage. It is reported that the probiotic cultures exposed to spray drying show increased sensitivity 
to cell wall, cell membrane and increased DNA damage (Abee & Wouters, 1999). 
Loss of viability of probiotic organisms in the probiotic products are due to several reasons such as 
level of oxygen in the products, acidity of products, acid produced during refrigerated storage (post 
acidification), sensitivity to antimicrobial substances produced by bacteria and oxygen permeation 
through the package (Dave & Shah, 1997). Selection of suitable probiotic strains plays a major role in 
improving the viability of probiotic organisms in probiotic products. There are many techniques that 
have been put forward to improve the viability of probiotics strains, including the selection of acid 
and bile resistant strains, microencapsulation, the use of oxygen-impermeable containers, two-step 
fermentation, stress adaptation, and the incorporation of micronutrients such as peptides and 
amino acids. Apart from manipulation of probiotics strains, it has been found some substances are 
known to improve the viability of the probiotic microbes. Babu et al. (1992) have reported that 
papaya pulp and tomato juice stimulated the growth of Lb. acidophilus, resulting in higher viable 
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counts, improved sugar utilisation and shorter generation times. This stimulation can be due to 
greater availability of simple sugars like glucose and fructose and minerals including magnesium and 
manganese which acts as growth promoters to Lb. acidophilus. Bifidobacteria, one of the most 
commonly used bacteria in probiotic products, show poor growth in milk. The viability of B. longum 
improved when the 0.01% of baker’s yeast added to the milk (Shimamura, 1982).  
Ross Crittenden et al. (2006) studied the effect of microencapsulation (film-forming protein-
carbohydrate-lipid emulsion) on B. infantis survival rate. They found that the encapsulant protected 
B. infantis during non-refrigerated storage with exposure to oxygen and humidity. 
Probiotic animal feed is manufactured in the form of liquids and pellets. Pelleting, extrusion and 
complementary processes require pressures and high temperature which may affect the viability of 
probiotics. For instance, a typical feed for broiler chickens is processed at about 75-85 oC for 15-20 
min with a moisture content of 15%, before pelleting (Kosin & Rakshit, 2006). It is a significant 
challenge to maintain viability and survival of probiotic microbes during feed manufacturing. 
Thermophilic/thermotlolerant bacteria have the ability to withstand higher temperature during 
processing and storage. Selection of these microbes could enhance the viability of the probiotic 
products. Most of the thermophilic LAB has been studied for induced stress response, when exposed 
to heat shock. For example, a thermophilic probiotic strain (Lb. paracasei) showed 49% survival rate 
when subjected to spray drying at 80-85 o C (Gardiner et al., 2000).  
Though most of the thermophilic lactobacilli originate from dairy products, some thermotolerant 
bacterial species have been successfully identified in chicken intestines, which includes Lb. reuteri, 
Lb. thermotolerans, Lb. aminata sp. nov., and some varieties of Lb. paraplantarum (Niamsup et al., 
2003; Sow et al., 2005). Probiotic cultures exposed to sub-lethal treatment demonstrate better 
adaptability and viability during lethal treatments of food/feed processing. For an instance, Lb. 
paracasei subjected to pressure pre-treatment showed higher survival rate than untreated cells 
when exposed to high temperature at 60 oC (Ananta & Knorr, 2004). Maintaining the viability of the 
probiotic microbes during spray drying and freeze-drying in feed processing is a major challenge for 
the industry. Pascual et al. (1999) showed that the glycerol and skim milk that act as cryoprotective 
agents could be used to preserve the probiotic strain in the freeze-drying. Probiotic microbes can be 
protected from the stress and spray-drying by composite carrier matrix systems which include 
different food matrices.  
Dehydrated glucose syrups microencapsulated with the probiotic strains showed greatest survival 
rate compared to other carbohydrates used during spray- drying (Boza et al., 2004).  
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Prebiotics in combination with probiotics is called synbiotics. Use of prebiotics in probiotic culture 
may increase the growth and survival of the probiotic microbes. A study of the in vitro fermentation 
properties of a commercial prebiotic  demonstrated Xylooligosaccharides and lactoluse were 
responsible for increased cell numbers in Bifidobacterium whereas fructooligosaccharides were 
found to be responsible for increased lactobacilli population (Rycroft et al., 2001). Resistant starches 
(prebiotics) used in the feed industry offer a surface for adherence to the probiotic microbes during 
processing, storage and transit through the upper regions of the gastrointestinal tract improve the 
viability of the probiotic microbes (Crittenden et al., 2001).  
2.5.2 Bioactive compounds/metabolites in animal probiotic products 
The production of metabolites by different probiotic microorganisms is considered to be a primary 
mode of action against pathogenic organisms present in the GIT as well as in food. These 
metabolites such as organic acids ( lactic acid and acetic acid) carbon dioxide, ethanol hydrogen 
peroxide,  diacetyl, acetaldehyde, acetoine, reuterin, reutericyclin are low mass molecules. 
Bacteriocin, one of the important metabolites with high molecular mass has extensively been used in 
the food industry as biopreservative (Suskovic et al., 2010). Utilization of antimicrobial metabolites 
in probiotic products in animal and human health applications has increased. These antimicrobial 
substances are used in the probiotic industry to control pathogenic organisms in the GIT and 
urogenital tract. The most important and best characterized antimicrobials produced by LAB are 
lactic acid and acetic acid. Organic acids such as formic acid, acetic acid, lactic acid, propionic acid, 
benzoic acid and free fatty acids are produced from sugars, amino acid and/or lipid metabolism in 
bacterial cells (Ray et al., 2000).  
Tharmaraj and Shah (2009) studied the effect of probiotics on pathogenic and spoilage bacteria. 
They found that the varying quantities of organic acids (acetic, lactic, formic, propionic, butyric, 
benzoic, and phenyllactic) secreted by probiotic microbes (Lb. acidophilus, Lb. casei, Lb. paracasei 
subsp. paracasei, B. animalis, and Propionibacterium freudenreichii subsp. shermanii ) were 
responsible for inhibiting the growth of pathogenic and spoilage microbes such as E. coli, S. 
typhimurium, S. aureus, and B.cereus. Secretion of antimicrobial substances is one of the most 
studied components in the anti-pathogenic activity of probiotic bacteria. Lb. fermentum strain SRJ-
23 showed significant antimicrobial activity against human pathogenic bacteria such as B. subtilis, E. 
coli, and S. aureus by producing proteinaceous substance like bacteriocin which is a characteristic 
feature of many lactobacilli (Purohit et al., 2012). BIF is a novel protein secreted by Bacillus longum 
strain BL2928 inhibited the interaction between E. coli and human epithelial cells (Fujiwara et al., 
1997).  
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Production of short-chain fatty acid (SCFA) metabolites by probiotic bacteria have an important 
protective function in the intestine and exert anti-inflammatory effects in different animals (Licciardi 
et al., 2010). SCFA includes butyrate, acetate and propionate. The butyric acid-producing anaerobic 
bacterium, Faecalibacterium prausnitzii is a novel probiotic used for the treatment of inflammatory 
bowel disease (Neish, 2004). Lipophilic compounds secreted by Bifidobacterium strains (CA1 and F9) 
have strong antimicrobial activity against S. typhimurium SL1344 and E. coli 1845 (Lievin et al., 2000). 
Though different probiotics exhibit different mechanisms of action to confer health benefits to the 
host animal, they are host-specific and strain-specific in their action. Selection of probiotic organisms 
with a combination of different modes of action may amplify the protective range of bio-therapeutic 
preparations (Filho-Lima et al., 2000). 
2.5.3 Quality control of animal probiotics products 
Testing for an adequate number of viable microbes present in a probiotic product throughout its 
production cycle and storage has generally been used as the only way to measure the quality of 
commercial probiotic products over the years. Though the viability of probiotic microbes in probiotic 
products plays an important role in quality issue, it is not the only criterion for quality assurance. 
Probiotic strains should be able to deliver the functional health characteristics for which they were 
originally selected. Strain resistance against gastric acid and bile salt can be determined by in vitro 
testing. Advancement in molecular techniques can also be used to examine strain stability. To 
develop an effective quality control system other functional properties of probiotics such as 
adhesion characterization, immunogenic effects and competitive exclusion have to be studied. 
However, probiotic microbes exhibit host-specific and strain-specific differences in their actions. 
Maintaining strain characteristics of the probiotic microbes is considered to be an important factor 
to deliver desired health effects. Some studies reveal that dried probiotic preparations may have 
contaminants (Arthur et al., 2002). Therefore, it is necessary for careful identification of strains via 
hygienic practices to avoid contamination. 
In order to measure the functionality and safety of the probiotic products used in the animal 
feeding, preliminary in vitro screening could be done to measure the following parameters: adhesion 
studies, survival in the GIT, antimicrobial activity and antibiotic susceptibility. Identification and 
characterization by advanced molecular methods such as microarrays improve the detection of 
multiple characteristics of probiotic strains. It has been reported that the organisms cited in the 
labels of certain probiotic products have not been found within the product and often the products 
contain species other than those claimed on the label (Huff, 2004; Wannaprasat et al., 2009). 
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Therefore, correct labelling of the probiotic product and the name of the exact taxonomic species 
with internationally accepted nomenclature is indispensable to avoid confusion and 
misidentification. It is recommended that the claim made by the producer about the preparation 
should reflect the actual composition of the product until the expiry date maintained in the 
recommended storage conditions with a decrease of one or two logarithmic units  maximum (Czinn 
et al., 2009). 
Efficacy of the probiotics may be affected by the dose, timing and duration of the administration of 
probiotics and the age of the animal. Higher dose of probiotics given for a short time seemed to be 
more effective in controlling acute infectious diarrhoea than lower doses of administration (Sazawal 
et al., 2006). New-born animals are more susceptible to environmental pathogens. Administration of 
probiotics for new-born animals could help in colonization of the bacteria which can modulate 
expression of genes in epithelia cells thus creating a favourable habitat for themselves (Siggers et al., 
2007).   
Adhesion characterization of probiotic microbes is an important quality control method for assessing 
the effect on the gut barrier. Tuomola  et al. (2001) studied the adhesion ability of some common 
probiotic strains by using a human colon carcinoma cell line (Caco-2) and human ileostomy 
glycoproteins as an in vitro model for intestinal epithelium and mucus respectively. Lb. casei showed 
higher adhesive characteristics amongst tested microbes.  
2.5.4 Safety of Animal Probiotics Products 
Most of the probiotic microbes used in animal probiotic products are considered to be safe, while 
some of the microbes such as Enterococci species and B. cereus have exhibited some problems when 
used as probiotic microbes. B. cereus is associated with the production of an emetic toxin and 
enteric toxin and the Enterococci species may be responsible for harbouring transmissible antibiotic 
resistance (Arturo et al., 2006). Microorganisms used in probiotics such as Lactobacilli, Lactococci, 
Bifidobacterium and yeast are classified as Generally Regarded As Safe (GRAS). Though some 
microbes including Bacillus, Enterococcus, Streptococcus and other spore-forming bacteria have not 
been categorized under the GRAS status, they have been used in the probiotics industry (Snydman, 
2008). Therefore safety and quality of the probiotic products has become important and the safety 
evaluation of probiotics use has already been implemented in different countries. 
In the USA, specific utilization of microorganisms for human consumption should possess the GRAS 
status regulated by the Food and Drug Administration. A similar approach has been introduced in 
Europe where European Food Safety Authority (EFSA) has introduced the concept of Qualified 
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Presumption of Safety (QPS) similar in purpose to the GRAS approach. The QPS system is considered 
to be more flexible as it takes into account number of additional criteria to evaluate the safety of 
bacterial probiotics. Those additional criteria include history of safe use in the food industry and the 
development of antibiotic resistance or virulence determinants (Wassenaar & Klein, 2008). 
In its recent updates EFSA has listed microorganisms that are safe to use in animal feeds (Table 2.1). 
The status of some microbes has been updated and some microbes have even been excluded from 
the list. For example, bacterial species such as Lb. lactis and Bacillus amyloliquefaciens which already 
held QPS status have been reviewed for their safety usage and extended their QPS status with some 
conditions. Furthermore, A. oryzae has been excluded from the QPS list because of its potential for 
mycotoxin production (EFSA, 2012). 
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Table 2.1   Microbes that are claimed as safe to use as probiotics in animal feeds certified by EFSA 
EFSA (2012). 
Genus Species 
Lactobacillus Lb. acidophilus 
Lb. amylolyticus 
Lb. amylovorans 
Lb. brevis 
Lb. buchneri 
Lb. casei 
Lb. bulgaricus (L.delbrueckii subsp. bulgaricus) 
Lb. casei rhamnosus (Lb. rhamnosus) 
Lb. delbrueckii subsp. lactis 
Lb. farciminis 
Lb. fermentum 
Lb. helveticus 
Lb. mucosae 
Lb. paracasei 
Lb. pentosus 
Lb. plantarum 
Lb. reuteri 
Lb. sakei 
Lb. salivarius 
Bifidobacterium     B. animalis 
B. longum 
Streptococcus   S. cremoris (L. lactis subsp. cremoris) 
S. thermophiles 
Bacillus  B. subtilis 
Pediococcus  P. acidilactici 
P. pentosaceus 
Propionibacterium  P. freudenreichii shermanii 
Saccharomyces  S. cerevisiae 
Kluyveromyces   K. marxianus var. lactisK1 
K.marxianus-fragilis 
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Generally probiotic microbes are considered to be responsible for four types of potentially negative 
side effects; gene transfer, systemic infections, deleterious metabolic activities and excessive 
immune stimulation in susceptible individuals (Marteau & Boutron-Ruault, 2002). One hypothetical 
risk associated with probiotic use is antibiotic-resistance gene transfer taking place between 
probiotic and pathogenic bacteria and this is considered to be a major area of concern. Plasmids 
containing antibiotic resistance genes have been discovered in LAB. Although antibiotic resistant 
genes have been found in Lb. acidophilus, Lb. reuteri, Lb. plantarum and Lb. fermentum isolated 
from feces of animals, raw meat, and silage (Gevers et al., 2003), the transfer of the Lactobacillus 
plasmids to pathogenic microbes is quite rare (Dessart & Steenson, 1991; Mathur & Singh, 2005). 
However, transfer of lactose fermentation plasmids to Lb. casei, and transfer of bacteriocin 
production to Lb. johnsonii have been reported (Ahn et al., 1992).  
Hypothetical risk of bacteremia and endocarditis by the use of probiotics have been reported and 
species of LAB, Enterococcus species and Bifidobacteria have been identified as cause of bacteremia 
and Endocarditis (Cannon et al., 2005). However there have been no studies to prove that these 
microbes are actual cause of bacteriamia and endocarditis. Sullivan and Nord (2006) studied 
Lactobacillus bacteremia with the probiotic microbes such as Lb. paracasei subsp. paracasei, Lb. 
acidophilus NCFB 1478 and Lb. rhamnosus strain GG. They concluded there was no evidence for 
Lactobacillus bacteremia and it could instead be due to the polymicrobial action. 
In addition to these risks associated with probiotic use, some theoretical risks have been raised with 
the use of probiotics include the potential for transmigration, production of undesirable metabolites 
in GIT and adverse immunologic effects. Therefore, it is required to have universally accepted 
regulatory systems to monitor the probiotic safety. 
2.6 BBAN 
BBAN is fresh, living and liquid animal probiotics produced by BioBrew Ltd which claims the use of 
BBAN improves health and overall wellbeing of animals. BBAN contains multi species and multi 
strain of LAB and yeast (4 LAB species and 3 yeast species). This animal probiotic product is available 
in 5, 10 and 20 litre plastic containers for consumers. BBAN does not need any special storage 
requirement and shed conditions are appropriate for storage. Containers have to be tightly capped 
and stored out of direct sunlight. BBAN is suitable for oral application in all domesticated species at 
all stages of development and may be administered via stock water, feed, or direct drenching. 
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BBAN production process 
       
 
           Stage 1 (Activation) 
 
 
 
 
 
 
    
  LAB fermentation    yeast fermentation  
  Sugar – 1 kg    Sugar – 1 kg  
  Seaweed- Pinch    Seaweed- Pinch  
  Buckwheat- Pinch    Buckwheat- Pinch  
  Inoculum –ABY-1 (6.25)    Melody  culture (12.5 g) 
  Average pH : 3.82       Average pH :3.36      
1 kg sugar is diluted in 20 litre water (Density =5 w/v %) 
brewing day = 1 day 
       
 
       Stage 2 (Expansion) 
 
       
    LAB fermentation    yeast fermentation  
   Molasses-10 litre    Molasses-10 litre  
   Dolomite- 25 g    Temperature 250C   
   Salt- 50 g    Average pH: 4.29  
   Average pH: 4.17       
   Temperature 370C        
10 litre molasses is diluted in 200 litre water (Density = 5 w/v %) 
brewing days=2 days (for different lot -more days) 
       
Stage 3 (Production of mixed culture) 
   LAB fermentation 
   (40 litre)    
yeast fermentation 
(20 litre)  
 
 
       
       
      50 litre molasses is diluted to 1000 litre water (density=5 w/v %) 
                                             Temperature 37oC       
                                             Brewing days= 3 days       
                                             Average pH=3.6-3.9  
       
Figure 2.1     Steps involved in standard commercial BBAN production. 
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Production of BBAN involved several steps. Each step is different from other steps in terms of 
fermentation temperature, number of fermentation days and ingredients(Figure 2.1). 
   Stage one/initial fermentation - one day 
   Stage two - 2-3 days 
   Stage three/Mixed fermentation - 3-4 days 
   Storage/shelf-life - one month 
Production of BBAN is a three stage fermentation process. Commercial  LAB(ABY-1) and wine yeast 
(Melody) are used as starter cultures for BBAN production. In the first stage, using sugar based 
medium,starter cultures are normally grown in individual containers at different temperatures for 
one day. stage 2 production is expansion of stage 1, LAB and yeast are fermented in parallel in the 
molasses media for 2-3 days. temperature in both stage 1 and 2 is maintained at  37oC  and 250C for 
LAB and yeast fermentation respectively.however,  37oC is maintained in stage 3 in which fermented 
products of stage 2 are combined together and allowed to ferment for  3 days. At the end of mixed 
fermentaion final product is ready to use and BBAN is decanted in the plastic containers. 
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Chapter 3 
Microbiological quality and safety of the probiotic product 
3.1 Introduction 
The probiotic market is expanding year after year with an increasing variety of products available for 
different host species. Probiotics are “live microorganisms which, when administered in adequate 
amounts, confer a health benefit on the host” (FAO/WHO, 2001). In order to attain therapeutic 
health benefits from probiotics there should be sufficient number of viable microbes present during 
production and storage (Ljungh & Wadström, 2006). However the determination of the number of 
viable microbes required to be present in a product to ensure efficacy is subject to debate and some 
countries have their own national standard to set the number of viable microbes in a “probiotic” 
product. For example, the recommended level of viable microbes in commercially available 
probiotics in Canada is 109 CFU per serving (CFIA, 2009) whereas the minimum bacterial count of the 
Chinese national standard for probiotic products is 106 CFU/g (Chen et al., 2014). In general, a viable 
cell population of microbes with probiotic characteristics between 106-108 CFU/ml is considered 
sufficient to be efficacious.  
The determination of viable cell concentration in probiotic products is critical in quality evaluation 
(Champagne et al., 2011). However, many probiotic products in the marketplace with low microbial 
counts, i.e., poor quality, have been reported when products are independently examined through 
quality testing (Coeuret et al., 2004). Deficiencies included inaccurate labelling or fewer viable 
microbes than the amount declared by the manufacturer and no information whether the viable 
counts were present until expiry date or at the time manufacture (Chen et al., 2014; Wannaprasat et 
al., 2009). 
Very few studies have been conducted on quality of animal probiotic formulation when compared 
with human probiotics. However, quality studies of animal probiotics are equally as important as 
human probiotic studies. Poor quality products not only reduce the beneficial effects from probiotic 
use, they also challenge the safety of the target organisms. Animal probiotics should be of especially 
high quality because of administration of poor quality probiotics in farm animal may not yield 
desired outcome.  
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The primary objective of this project was to test the microbiological quality for the commercial 
animal probiotics (BBAN) in terms of viability assessment at many stages of production for each 
batch until its shelf-life expiry. 
3.2 Materials and methods 
3.2.1 Growth media 
3.2.1 1 MRS agar plates 
De Man, Rogosa and Sharpes (MRS) agar (De Man et al., 1960) was used to detect and enumerate 
Lactobacillus colonies. MRS agar media was prepared either by dissolving 62 g of MRS agar in 1 litre 
of dH20 or by adding 15 g of bacteriological agar with 52 g of MRS broth in 1 litre of distilled water. 
All media were supplied by Oxoid Ltd. (Hampshire, England) and sterilised by autoclaving at 121 oC 
for 15 min.   
3.2.1.2 YGC plates 
Yeast Glucose Chloramphenicol (YGC) agar was used to enumerate yeast colonies. YGC plates were 
prepared by combining 5 g/l of yeast extract, 20 g/l glucose and 15 g/l agar in dH20. pH was adjusted 
to 6.6 before autoclaving and just before pouring into plates, 50 mg/l of chloramphenicol was added 
to YGC to inhibit bacterial growth.  
3.2.1.3 PDA plates 
In addition to YGC plates, Potato Dextrose Agar (PDA) plates were used to enumerate yeast counts in 
the product. Also PDA plates were used to detect Rhodotourula rubra presence in the product. 
3.2.1.4 MacConkey agar 
MacConkey agar was used to detect gram negative bacteria (especially, E.coli) in the sample/product 
3.2.1.5 Baird-Parker agar 
Baird-Parker agar is a selective agar media to detect the Staphylococci species. Especially, Baird-
Parker agar was used to find out if Staphylococcus aureus was in the sample 
3.2.1.6 3M Petrifilm     
In addition to these selective agar media, 3M petrifilm plates were used to check whether the 
product contained any foodborne pathogens. 
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3.2.2 Production schedule 
BioBrew Ltd. is a Commercial animal probiotic company which has four manufacturing sites in New 
Zealand located in Canterbury, Balclutha, Waikato and Taranaki (www.biobrew.net.nz) 
Manufacturing plant in Canterbury and Waikato are the chief production sites and production of 
BBAN involved several steps. Each step is different from other steps in terms of fermentation 
temperature, number of fermentation days and ingredients. 
   Stage one/initial fermentation - one day 
   Stage two - 2-3 days 
   Stage three/Mixed fermentation - 3-4 days 
   Storage/shelf-life - one month 
3.2.3 Sampling 
Sampling during different stages of production and over the duration of storage was undertaken to 
enumerate viable counts of probiotic microbes present in the product. Sample collection began from 
August 2013 to March 2014 for eight months at the Canterbury manufacturing site. Samples at many 
stages of production were collected in the plastic test tubes and tested immediately after brought to 
the laboratory. Samples for shelf life were stored in the laboratory environment in the plastic 
container. 
Three consecutive batches of BBAN were sampled for quality testing from day one of first stage of 
formulation to 30th day of shelf-life. Subsequently, sampling and testing was made at the end of each 
stage and weekly during storage for the different batches of probiotic products produced for eight 
months. 
Sampling across other manufacturing sites was made for comparative quality testing for the 
probiotic formulation with same production stage. This was done by collecting samples from all 
other manufacturing sites every month for three months. 
3.2.4 pH analyses 
The pH of the samples was measured using Orion 3-Star pH meter (Thermo Fisher Scientific Inc., 
USA) after calibrating with commercial pH 4.0 and 7.0 buffers (Thermo Fisher Scientific, MA, USA). 
pH of the product must of monitored to make sure the viability of the microbial counts is not 
affected by the low pH which  put the cells in stressful conditions resulting loss of viability. 
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3.2.5 Enumeration of LAB and yeast 
For plate counting, 100 µl of BBAN sample was mixed with 900 µl of peptone water (0.1%). The 
samples were then serially diluted and appropriate dilutions (up to 10-8 cells/ml) were spread onto 
different agar media. Spreader (hockey stick) was used to spread sample evenly onto the agar plate. 
MRS agar plates were incubated under anaerobic conditions at 37 oC for 48 hours whereas YGC 
plates were incubated under aerobic condition at 25 oC for 48 hours. Anaerobic conditions for MRS 
plates were maintained using click-clack jars and AnaeroGenTM sachets (Oxoid Ltd, Hampshire, UK). 
Subsequently, colonies were manually enumerated and yeast and bacterial concentrations in the 
original sample was estimated. 
3.2.6 Safety tests 
BBAN sample (1000 µl) was pipetted onto the MacConkey agar, Baird-Parker Agar and 3M petrifilm. 
Spreader was used to spread the sample evenly on agar plates and petrifilm. After incubation at 37 
oC for 48 hours, plates were inspected for any possible pathogens present in the sample. 
3.2.7 Statistical analysis 
Statistical analysis of data was carried out using Minitab (Minitab version 17, Minitab Inc.). The 
comparisons of differences between the means of the treatments were tested by analysis of 
variance by the General Linear Model (ANOVA-GLM) at the significance level of P < 0.05. Grouping 
was done using Tukey’s Method at 95.0 % confidence level. 
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3.3 Results 
3.3.1 Changes in pH during production and over the storage period of time 
Average pH value during different stages of production and storage period varied between lactic 
acid and yeast fermentation. At the end of stage 1 of lactic acid fermentation, pH of the product 
dropped from 6.1 to 3.82 and went up to 4.17 in stage 2 (Figure 3.1).  
 
Figure 3.1     Changes in pH value in lactic acid fermentation during production and over the 
storage period of time. 
 
pH changes in yeast fermentation also showed similar pattern where pH range was 3.36 - 4.29 
between stage 1 and stage 2, respectively (Figure 3.2). However, there were no significant 
differences in pH value between mixed fermentation and different storage days. Low pH value is a 
good indicator of how acidic the product is. Shelf-life of the product has been designated one 
month. Both LAB and yeast acidified the product in combined cultures reaching a final pH of 
between 3.6 - 3.9 when the product was available for customers. 
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Figure 3.2     Changes in pH values in yeast fermentation during production and over the                                
storage period of time. 
 
3.3.2 The influence of storage on the survival of LAB in BBAN 
The data collected at the end of each stage and during storage at weekly interval was subjected to 
analysis. Average log number of bacterial and yeast cell numbers were obtained from several 
batches (Appendix A.1 and A.2).  
Generally lactobacilli fermentation as a single culture is undertaken using sugar media as a substrate 
and allowed to ferment overnight during stage 1. Most of the samples collected after several hours 
of fermentation at stage 1, estimated the number of viable count of 7.67 log CFU/ml. Molasses is 
used as substrate in step 2 fermentation and the fermentation lasts for 2-3 days. The average 
bacterial colonies (9.3 log CFU/ml) in step 2 was found to be higher than that of initial fermentation 
and difference in cell counts between stage 1 and 2 were significantly different (P < 0.05) (Figure 
3.3). 
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 Figure 3.3   Mean values of several batches. Bacterial cell concentration at many stages and over 
the storage period; a, b, c   superscript letters differ significantly (P < 0.05). 
 
Step 3 fermentation (mixed fermentation) is similar to stage 2 in terms of substrate and at the end 
of mixed fermentation BBAN is ready for marketing. There was a significant difference between the 
results obtained from stage 2 and mixed fermentation   (P < 0.05). In contrast, cell numbers in mixed 
fermentation did not differ statistically with different storage days and the average bacterial viable 
counts obtained were between 10.49 - 11.24 log CFU/ml (Figure 3.4).  
 
                                 A                                    B 
           
Figure 3.4   Typical LAB counts with 10-8 dilution of the BBAN samples at 14th (A) and 28th (B) day of 
storage days.  
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Changes in cell densities in stage 1 and 2 fermentation seemed to be not affecting the cell numbers 
at the end of mixed fermentation. Almost all the batches had sufficient lactobacilli numbers ranging 
from 10.49 ± 0.29 log CFU/ml of at the end of stage 3. 
To assess the stability of the BBAN, viability of the product tested until 30th day of storage. Log 
number of viable lactobacilli counts did not have significant differences between various storage 
periods until its expiry day and cell counts were observed 11.24 ± 0.12 log CFU/ml at the end of 
shelf-life. Therefore, it is certain that this BBAN contained viable lactobacilli counts higher than 
minimum recommended dosage until its expiry day. The results indicated that the influence of 
storage did not affect the viability of the LAB in BBAN. There was no reduction in bacterial counts; 
rather product had consistent bacterial counts towards the end of shelf-life. 
3.3.3 The influence of storage on the survival of yeast culture in BBAN 
The BBAN produced by BioBrew Ltd consists of multi-species and multi strains to diversify the health 
benefits. It contains LAB and yeast to deliver health benefits to the farm animals. 
The total viable yeast colonies contained in BBAN in stage 1 and stage 2 ranged between 9.97-10.24 
log CFU/ml. There was no significant difference was detected between initial fermentation and stage 
2 as well as between mixed fermentation and day 1 of storage (Figure 3.5).  
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Figure 3.5   Mean values of several batches. Yeast cell concentration at many stages 
and over the storage period of time.  a, b, c  superscript letters differ significantly (P < 
0.05). 
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 In general, population of yeast tended to decrease when the storage period of the BBAN increased. 
The total yeast counts found in BBAN in first and 28th of storage day were 8.02 ± 0.31 and 5.47 ± 0.19 
log CFU/ml respectively (Figure 3.6). Therefore, it is clear, that the growth of yeast colonies has been 
significantly affected in co-culture. 
Statistically significant difference in cell numbers was obtained between stage 2 and mixed 
fermentation and day one storage and other storage days (P < 0.05). Influence of storage on viability 
of yeast was found to be negative and yeast cell numbers from first week of storage until its shelf-
life did not show statistically significant difference. 
 
 
A           B 
                               
Figure 3.6 Overview of viable yeast cell colonies at stage 1 (A) and 21st (B) day of storage with 10-7 
and 10-2 dilution, respectively. 
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3.3.4 Viability at many stages of production and at the end of shelf-life 
 
The total LAB and yeast counts in BBAN samples found at the end of expiry day were 11.24 ± 0.12 
and 5.47 ± 0.19 log CFU/ml respectively. It was noted there was significant differences in LAB and 
yeast counts at the expiry date (Figure 3.7).  
 
 
Figure 3.7 Lactobacilli and yeast cell concentrations at different stages of production and at the 
end of shelf-life. 
 
3.3.5 The influence of extended storage on the viability of LAB and yeast 
Viability of the bacterial strains in the product did not change with storage day until its expiry of the 
product. The study conducted to determine the viable counts of LAB and yeast for the extended 
shelf-life. Total viable counts of LAB and yeast in the product with two weeks extended storage 
remained same as it was found on the eve of its expiry date (Figure 3.8). There were no reductions in 
LAB and yeast cell counts when the product with 2 weeks extended shelf-life. 
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 Figure 3.8 Average viable Lactobacilli and yeast cell concentration (log CFU/ml) of several batches 
with extended storage. 
 
3.3.6 Comparison of different production sites for viability assessment  
Viability of the product amongst different production sites were consistent and cell counts of LAB 
and yeast ranged between 9.43-11.23 and 5.29 -5.69 log CFU/ml, respectively. Yeast cell counts did 
not differ significantly amongst different production sites. However, LAB cell densities in Canterbury 
production sites were found to be slightly higher than that of other productions sites (Figure 3.9). 
Number of samples analysed in Canterbury site was much higher than that of other sites. Production 
of BBAN in Canterbury site and other sites had similarity in the viability analysis and there were no 
significant differences between various production sites. 
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Figure 3.9 Overview of the log number of viable LAB and yeast cell numbers in the animal 
formulation obtained from different production sites. 
 
3.3.7 Viability assessment on monthly basis 
Investigating the microbial quality analysis on a monthly basis and evaluation of microbial cell counts 
on 7th and 28th day of storage were analysed. LAB cell numbers in the study period consisted > 1010 
log CFU/ml at 7th and 28th days of storage except month of August where cell counts at 7th day of 
storage was 109- 1010 log CFU/ml (Figure 3.10). Bacterial cell numbers between first and last week of 
storage did not show significant difference whereas yeast cell concentrations between 7th and 28th 
storage days, differed significantly. In most cases, yeast cell numbers ranged between 104 to 106 
CFU/ml  until its expiry day in all months except months of November and December 2013 in which 
cell concentrations were >106  at 7th day of storage. 
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 Figure 3.10 Overview of the log number of LAB and yeast cell numbers for the BBAN produced in 
different months (study period) in Canterbury production site. 
 
3.3.8 Safety assessment 
Assessment of safety in the BBAN was measured for the product collected from all four production 
sites at various stages of production. Product tested for general foodborne pathogens such as gram 
negative bacteria (especially E. coli and total Coliform) and Staphylococci species showed negative 
and none of bacterial foodborne pathogens detected in the product. However, unusual pink colonies 
were observed in two batches of BBAN produced in the month of October 2013. In order to identify 
these unknown pink colonies, they were isolated, stained and looked under the microscope and the 
digital images of these colonies were taken (Figure 3.11 and 3.12). Morphological appearance, 
characteristics of these suspected organism and literature review suggested that contamination of 
the product could be due to Rhodotorula species (Banzatto, de Freita, & Mutton, 2013; Wirth & 
Goldani, 2012). 
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 Figure 3.11   Overview of pink colonies found in the BBAN produced in the month of October 2013. 
 
   
 
Figure 3.12   Digital images of suspected pink colonies tested under a microscope (×100) 
 
Further literature review showed that BBAN might have been contaminated by R. rubra (R. 
musigelaneous). This would have been confirmed by using molecular technique and sequencing 
technique. This problem was observed 2 months after the study started. Limited time period forced 
to focus on how to manage this problem in the future. 
3.3.8.1 Management of contamination 
According to the literature, R. rubra has strong affinity with plastic containers and is prevalent 
everywhere (Wirth & Goldani, 2012). BBAN is decanted in different size of plastic bottles. Following 
steps were taken to manage the contamination in production sites.  
Rescheduling the production technique 
• All the production was temporarily suspended 
• All the containers including IBC containers were soaked and washed by bleaching 
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• Once the production resumed, switched to two step fermentation in contrast to usual three 
step fermentation. This lasted at least for one month 
• Unloading used containers were separated from production site and washed by bleaching 
before reuse. 
• To avoid cross contamination in the laboratory 
- Fresh culture media was prepared 
- Fresh 0.1% peptone water was prepared 
- As usual all the tips, micro tubes, pipettes were autoclaved  
- Routine good lab practice was undertaken 
 
3.4 Background of R. rubra 
Rhodotorula is ubiquitous yeast species commonly found in water, air, soil, ocean and other 
environmental sources. R. rubra which produces characteristic pink to red colonies have long been 
considered as non-pathogenic and used in the carotenoid production (Wirth & Goldani, 2012). 
Carotenoid which has anti-carcinogenic and pro vitamin properties have been successfully  produced 
by R. rubra with different culture media such as molasses, sugarcane juice, and syrup as substrates 
(Banzatto et al., 2013). It should be noted that BBAN uses molasses as a substrate for microbial 
fermentation. Recent studies described Rhodotorula species have been identified as an emerging 
pathogen in human and animals. It is reported that these species are responsible for skin and lung 
infections in animals and fungemia disease in immunocompromised patients (Wirth & Goldani, 
2012). Among farm animals there are reports of skin infection in chicken; lung infection and otitis in 
sheep and cattle (Table 3.1).  
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Table 3.1   Infection caused by Rhodotorula species in human and animals. 
Species Target organism Disease Reference 
R. mucilaginosa  
Human 
Fungemia (Wirth & Goldani, 2012) 
R. glutinis Endocarditis 
 
 
R.mucilaginosa 
 (R. rubra) 
Chicken Skin infection (Aruo, 1980) 
Sheep Lung Infection (Garg, 1980) 
Sea lion Epididymitis (Alvarez-Perez et al., 
2010) 
Cat Dermatitis 
 
 
3.5 Discussion  
In recent years, application of fermented liquid feed in animal nutrition has been increased 
dramatically due to number of reasons. Using cheaper ingredients, aiming to reduce the use of 
antibiotics in animal feeds and use of environmental friendly ingredients are some of the reasons. 
BBAN is a fermented liquid probiotic widely used as a functional food in domesticated animal 
nutrition. Amongst different quality control parameters, viability of the probiotic strains is an 
important microbiological quality parameter of the probiotics (Tuomola  et al., 2001). 
Quality study for the samples collected continuously and periodically would ensure a consistently 
high-quality product. In our study we evaluated quality analysis of the BBAN with each stage of 
production until and beyond its expiry date. Samples collected routinely to determine the viability 
assessment.  
In this study, we evaluated 23 batches of BBAN (from initial fermentation until its shelf-life) 
produced between August 2013 and March 2014 in Canterbury production site and several random 
samples from other production sites. More than 300 samples were analysed and Plate counting on 
Selective agar media were used to enumerate the colonies of LAB and yeast found in the 
formulation. LAB were cultivated on lactic acid medium and were enumerated based on colony 
morphology. 
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Although modern methods are rapid and able to produce higher number of cell counts (Vanhee  et 
al., 2010) plate count method is used traditionally to quantify the viable cell numbers especially, it is 
preferable when higher number of samples for the routine determination of colony counting. 
Exposure of LAB starter culture to the different substrates and fermentation involving 3 steps 
ensures viability of the LAB. Major end products of the bacterial fermentation such as lactic acid 
lower the pH and before the media reaches its minimum level of pH, the next stage of fermentation 
is undertaken. The volume and density of the culture media varied between different stages of 
production. Molasses was diluted with water to a final density (5% w/v) before mixed fermentations 
started. Gradual adaptation to the low pH environment and supply of enough substrate for the 
growth kept the LAB viable until its expiry date. Consistent pH throughout the storage period was 
recorded and pH range varied between 3.6-3.9. 
Health benefits from probiotic use depend on how the viability of a product is maintained until its 
shelf-life. Determination of minimum dose of probiotics is critical to attain intended health benefit 
from probiotic use. Although a number of following factors determine minimum dosage, there is no 
internationally recognized regulatory body to determine the minimum dosage.  
1. Target organism (probiotic for human use / animal use) dosage is host dependent as well as strain 
specific. 
2. Target site of body part (for an example probiotics intended to use in stomach would need higher 
number of viable counts than the target site of mouth) 
3. Strain used in probiotics - In order to get intended/given functional health benefits from probiotic 
use, dosage determination may be influenced by what strains used in the probiotic formulation and 
minimum dosage likely to vary with individual probiotics (Sanders et al., 2007).    
4. Country of origin- expectation of minimum viable counts for the probiotic products vary with 
manufacturing country. Recommended level of viable counts of microbes in commercially available 
probiotics in Canada is 109 CFU per serving  (CFIA, 2009)  whereas minimum (bacterial counts) 
quantitative requirement of the Chinese national standard for the probiotic product remain 106 
CFU/g (Chen et al., 2014). 
Although the viable cell count level required to guarantee the health benefits from  probiotic use has 
not been conclusively established (Reid, 2008), in general, probiotic formulations have been 
demonstrated to be efficacious, when the product contained total viable cell counts greater than 
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106-108 CFU/ml at the end of its shelf-life (Champagne et al., 2011).The average total number of 
cultivable LAB was found to be 1010 - 1011 CFU/ml for all the BBAN analysed between several 
batches. Log number of viable lactobacilli counts did not significantly differ between various storage 
periods until its expiry day and average cell counts were observed 11.24 ± 0.12 log CFU/ml at the 
end of shelf-life. Viability of LAB strains contained in all BBAN samples measured by traditional 
methods remained above 1010 cells per ml until their expiry dates. Hence, this microbial cell counts 
are substantially greater than the suggested minimum dose for probiotic effect. 
Selection of multi-strain and multi-species for probiotic product development enhances the 
protective range and acts as a broad spectrum product. In order to diversify the beneficial effects 
using multi-strain and multi-species, BBAN consist of Lactobacilli and yeast strains in the product. 
Yeast as a single culture is used in Initial and step 2 fermentation and average cell concentration 
reaches to 9.5 - 10 log CFU/ml. However, population of yeast started to decrease when it was used 
as co-culture in mixed fermentation. There have been reports of positive and negative influence 
between LAB and yeast on their growth by each other. Positive interaction by yeast on LAB includes 
production of amino acid and vitamin synthesis (Roostita & Fleet, 1996) as well as production of CO2, 
pyruvate, succinate and propionate which have stimulating effect on LAB growth (Leroy et al., 1993). 
On the other hand, galactose released by some LAB species may favour the growth of lactose-
negative yeasts (Marshall & Tamine, 1997). Though their mechanism of interaction is not well 
understood, it is obvious, the growth of yeasts was significantly affected in co-culture and the yeast 
species reached between 5.47 log CFU/ml and 8.02 log CFU/ml over the period of storage. 
In our study, stability assessment of bacterial counts over the storage period did not statistically 
differ and plate counts remained above 1010 cell counts/ml until their expiry days. Hence, the LAB 
growth seems to be not affected by the yeast in the co-culture and rather, positive interaction 
overwhelms negative influence of yeast. Results obtained from other production sites are in 
conformity with the results obtained from main production site. Mutual inhibition of growth has 
been reported as negative interaction between these two cultures. Compounds such as phenyl-lactic 
acid, 4-hydroxy-phenyl-lactic and cyclic peptides secreted by LAB have been reported to have 
inhibitive effect on yeast growth (Nielsen et al., 1998); while fatty acids produced by the metabolism 
of lipolytic yeasts have been affected the growth of LAB (Broome et al., 1979).  
Assessing BBAN for the stability of the yeast counts reduced by half amount at the end of its shelf 
life. It should be noted that the MSL of viable counts in the probiotics at the time of consumption 
should be approximately 106 CFU/ml  (Adhikari  et al., 2003; Vinderola et al., 2000). Average viable 
counts of yeast colonies were just below the MSL after one week of storage period towards the end 
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of shelf-life. An average log reduction in the number of cells 5.82 and 5.47 were obtained during 2nd 
and 4th week of storage. Although yeast counts in BBAN slightly lower than the MSL, combination of 
LAB and yeast acts synergistically to provide health benefits. Combination of low pH produced by the 
LAB plus the alcohol and CO2 produced by the yeasts collectively has inhibitory effect against many 
undesirable microorganisms (Ferreira & Viljoen, 2003). Plate count method enabled the 
enumeration of only viable yeast counts however, detection of viable non-culturable microbes by 
Solid Phase Cytometry (SPC) have also shown probiotic effects when the probiotics containing S. 
boulardii tested for quality analysis (Vanhee  et al., 2010). Secretion of protein involved in inhibition 
of Vibrio cholerae toxin (Czerucka et al., 1989) and increased production of the brush border 
disaccharidases (Buts & de Keyser, 2006) are some of the examples of probiotic effects by the viable 
non-culturable cells. 
Viability results obtained from the other production sites showed conformity with the Canterbury 
production site. All of the production sites had similar pattern of survival rate of LAB and yeast in the 
product. Assessment of stability of the product with extended storage period (up to 6 weeks) had 
interesting findings. While LAB counts were similar to 4th week of storage, yeast counts were found 
below the MSL at the end of 6th week. 
The safety assessment results of this study demonstrated the BBAN have not been contaminated by 
general foodborne bacterial pathogens. However, contamination by R. rubra was successfully 
identified over the period of study. Conditions favourable for this contamination was effectively 
identified and eliminated. Similar contamination issue was not reported again during the period of 
study 
3.6 Conclusions 
Final product of the BBAN had more than recommended number of LAB viable counts irrespective of 
the storage days. However, yeast cell densities was higher in the first week of storage and started to 
decline towards the end of expiry date. Overall yeast counts in the product were just below the MSL. 
Viability results obtained from the other production sites showed conformity with the Canterbury 
production site. Viable LAB counts in the BBAN with extended storage (6 week) were similar to 4th 
week of storage and yeast counts were found below the MSL at the end of 6th week. 
 The safety assessment results of this study demonstrated the BBAN have not been contaminated by 
general foodborne bacterial pathogens. However, contamination by R. rubra was successfully 
identified over the period of study. Conditions favourable for this contamination was effectively 
identified and eliminated.  
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In conclusion, the quality of the BBAN in terms of viability and safety satisfied the requirements for 
quality parameters. 
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Chapter 4 
Metabolite profiling 
4.1 Introduction 
The production of metabolites by different probiotic microorganisms is considered to be the main 
mode of action against pathogenic organisms present in the GIT as well as in food. Probiotics exert 
health benefits to the host organism through the production of metabolites such as organic acids 
(lactic and acetic acid), hydrogen peroxide, ethanol, diacetyl, acetaldehyde, acetoine, carbon 
dioxide, reuterin, reutericyclin, bacteriocins and short- chain fatty acid (SCFA) (De Jong & Badings, 
1990; Lindgren & Dobrogosz, 1990). Metabolites such as organic acids (lactic acid and acetic acid) 
carbon dioxide, ethanol hydrogen peroxide, diacetyl, acetaldehyde, acetoine, reuterin, and 
reutericyclin are categorized as low mass molecules whereas bacteriocin, one of the important 
metabolites and has extensively been used in the food industry as biopreservative, has been 
categorized as a metabolite with high molecular mass (Suskovic et al., 2010).  
The most important and best characterized antimicrobial metabolites produced by LAB are lactic 
acid and acetic acid. The effect of lactobacilli on C. jejuni growth demonstrated that the 
concentration of lactic acid produced by lactobacilli was sufficient to kill the foodborne pathogen in 
broiler chicken (Neal-McKinney et al., 2012). Furthermore, the combination of metabolites produced 
by Lb. plantarum was effective in reduction of Enterobacteriaceae in the GIT of piglets (Thu  et al., 
2011). Yeasts have shown to exhibit antagonistic activities against undesirable bacteria and fungi by 
producing antimicrobial compounds such as antifungal killer toxins or “mycocins” and antibacterial 
such as ethanol and CO2  (Hatoum et al., 2012). The BBAN contains both LAB and yeast culture.  Low 
pH from LAB fermentation and the alcohol and CO2 produced by the yeasts in combination have 
shown to be responsible for inhibition of many undesirable microorganisms (Ferreira & Viljoen, 
2003). 
SPME/GC-MS represents a novel method for studying metabolic profiles of biological samples. The 
aim of this investigation was to determine the volatile and non-volatile organic compounds found in 
the BBAN and to profile the diversity and nature of these compounds. 
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4.2 Materials and method 
4.2.1 Materials 
4.2.1.1 Non-volatile metabolites 
a) Lactic acid assay 
1. Buffer (25 ml, pH 10.0) + D-glutamate and sodium azide (0.02% w/v) 
2. NAD+ (contents was dissolved in 5.5 ml distilled water) 
3. D-Glutamate-pyruvate transaminase suspension (D-GPT) 
4. L-Lactate dehydrogenase suspension (L-LDH)  
5. D-Lactate dehydrogenase suspension (D-LDH) 
6. D-/L-Lactic acid standard solution (5 ml, 0.15 mg/ml of each) in 0.02% (w/v) sodium azide 
b) Ethanol assay 
1. Buffer (15 ml, pH 9.0) + sodium azide (0.02% w/v) 
2. NAD+ -Dissolve the contents in 12.4 ml of distilled water. 
3 Aldehyde dehydrogenase solution  
4. Alcohol dehydrogenase suspension   
5. Ethanol standard solution (5 ml, 5 mg/ml) - 0.5 ml standard solution was diluted with 50 ml 
distilled water. 
4.2.1.2 Volatile metabolites 
a) Internal Standard (IS) - Cis-3-hexenyl acetate 
Cis-3-hexenyl acetate (0.1122 g) 98% (Sigma Aldrich, New Zealand) was dissolved in 100 ml of 10% 
acetone in deionised water to form a stock solution. This was further diluted 20 times in deionised 
water to obtain a final concentration of 0.055 g/l. 
b) Buffer -Tartaric acid  
2.5 g of L-Tartaric acid ACS grade 99.5% (Sigma Aldrich, New Zealand) was dissolved in 500 ml of 
distilled water and adjusted to pH 3.5 with 4M sodium hydroxide. 
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c) Solvent  
Diethyl ether high purity grade 99.5% (BDH Prolabo, Belgium). 
d) Sulphuric acid (50%) 
Analytical grade H2SO4 (50 ml) was added to distilled water (50 ml) and stored at room temperature. 
e) Sodium chloride 
Crystalline sodium chloride AR grade (Merck, New Zealand). 
4.2.2 Methods 
4.2.2.1 Sampling 
Samples that were collected for microbiological quality testing was preserved in the freezer were 
used for metabolite studies. Samples at many stages of production, different storage period and 
samples from other manufacturing sites were used for this study. In addition, samples from control 
batches at many stages of production and different storage periods were also used for metabolite 
profiling studies. Stage 1 of control batch was prepared at Lincoln university laboratory and rest of 
the process made at Canterbury production site. Thus, two control batches were produced to 
compare the test results with the usual BBAN products. 
4.2.2.2 Non-volatile organic compounds 
a) Sequential D- and L-lactic acid assay 
Sequential D-/L-lactic acid (rapid) assay method (Megazyme International, Ireland, 2012) was used 
to determine the D- and L-lactic acid concentration in the selected BBAN samples according to the 
manufacturer's procedure. Samples collected from different sites with various stages of production 
were diluted 50 times. 1.5 ml distilled water, 0.5 ml buffer solution, 100 μl NAD+ and 20 μl D-GPT 
were added to the cuvette containing 100 μl sample. Instead of sample, 0.1 ml distilled water and 
0.1 ml standard solution was used as blank and control respectively. The absorbance at wavelength 
of 340 nm was recorded after 3 min of reaction (UVmini-1240 Spectrophotometer, Shimadzu). 
Subsequently, 20 μl D-LDH suspension and 20 μl L-LDH suspension were added and left for 5 and 10 
min interval, respectively. The absorbance was recorded and concentration of D- and L-lactic acid 
was determined from the calculation made according to the manufacturer’ instructions. 
b) Ethanol assay 
Ethanol assay procedure (Megazyme International, Ireland, 2012) was used to determine the 
concentration of ethanol present in the BBAN samples. Distilled water (2 ml), 200 μl of buffer 
solution, 200 μl of NAD+ and 50 μl of aldehyde dehydrogenase solution were added to the cuvette 
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containing 100 μl sample which was diluted 100 times.  Blank and control were prepared by adding 
100 μl of distilled water and 100 μl of ethanol standard solution, respectively. Cuvette was allowed 
for 2 min and the absorbance at wavelength of 340 nm was recorded (UVmini-1240 
Spectrophotometer, Shimadzu). Subsequently, 20 μl of alcohol dehydrogenase suspension was 
added and spectrophotometer reading was taken after 5 min. Concentration of ethanol was 
calculated according to the manufacturer manual instructions. 
4.2.2.3 Volatile Organic Compounds (VOC)  
Two GC–MS extraction methods were trialled to determine which method was most effective in 
profiling the volatile metabolites present in the BBAN samples.  Of the two extraction methods 
headspace solid phase micro-extraction (HS-SPME) was found to be more sensitive and efficient in 
metabolite profiling compared to the solvent extraction methodology proposed. 
a) Extraction of volatile metabolites with organic solvents 
In order to extract volatile compounds from the sample, 5 ml of BBAN sample was centrifuged and 
the supernatant was taken into a 10 ml glass tube. NaCl (4 g) and 2 ml of 50% H2SO4 was added and 
mixed well. Volatile compounds were extracted in 5 ml of diethyl ether high purity grade 99.5% (BDH 
Prolabo, Belgium) added to the glass tube and inverted 20 times. Air was then used to dry the ether 
layer concentrating this from 5 ml to 2 ml. 
The concentrated 2 ml ether layer was then transferred to a 2 ml gas chromatography vial and kept 
in a range hood for air drying until the final volume was 0.5 ml. It was then immediately capped and 
sealed with para film for analysis. 
b) Headspace Chromatography /SPME 
Samples collected at many stages of production, different storage periods and from different 
manufacturing sites were kept in the freezer at – 20 oC. Samples kept in the freezer were allowed to 
thaw in the fridge overnight at 4 oC. The following day samples from the fridge were centrifuged for 
5 min and 10 ml of supernatant were transferred to 15 ml centrifuge tubes ready for HS-SPME GC-
MS analysis. Cis-3-hexenyl acetate (0.055 g/l) was used as an internal standard (IS). 
Sample preparation significantly influences the HS-SPME extraction sensitivity and subsequent peak 
shape of volatiles on the GCMS. A reliable and repeatable analysis was required. To optimise the 
technique different parameters such as sample volume, concentration of IS, headspace volume, 
extraction temperature and extraction time were examined. 
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Comparison of initial sample extractions showed improved chromatographic performance with 
reduced sample volume minimising peak overloading. As such the IS amount added was reduced to 
ensure its peak area did not dominate. It was decided that 1 ml of sample in a total volume of 9 ml 
was the best extraction sample volume to use. Further tests also showed that increased extraction 
temperature and time resulted in improved sensitivity (Kopsahelis et al., 2009). Hence 60 oC for 45 
min was used instead of 30 oC for 30 min (initial experiments) in all subsequent sample analyses.  
4.2.2.4 GCMS parameters for headspace analysis 
The analysis of volatile compounds was determined using an automated HS-SPME GCMS technique, 
based on the work of Kopsahelis et al. (2009).  This adapted method utilised the addition of cis-
hexenyl acetate as an IS and involved sample dilution in a tartaric acid buffer to achieve consistent 
HS-SPME extraction between sample treatments and adequate chromatographic conditions for the 
VOC’s detected. 
Sample preparation involved pipetting 1ml of BBAN into 20 ml SPME sample vials followed by 7.98 
ml of tartaric acid buffer (5 g/l, pH 3.5), 20 µl of internal standard solution (55 mg/l) and 3 g of 
crystalline sodium chloride immediately prior to capping. Samples were then placed in a sample tray 
held at 8 °C awaiting extraction.  Samples were incubated for 45 min at 60 oC with their enclosed 
headspace exposed to a 2 cm long DVB/CAR/PDMS combination SPME fibre (p/n 57348-U, 50/30 µm 
thickness, 24 gauge, Supelco Bellefonte, PA, USA, through Sigma- Aldrich, Australia). During this 
exposure period the headspace volatiles, were adsorbed onto the fibre. Desorption of these volatiles 
occurred when the SPME fibre was inserted into the GC injection port for 10 min at 250 oC. 
GCMS analysis was carried out on a Shimadzu GCMS-QP2010 gas chromatograph–mass 
spectrometer (Shimadzu Scientific Instruments Inc, Japan) equipped with a Combi-Pal autosampler 
(CTC analytics AG, Switzerland) ready for automated SPME. GCMS solutions version 2.7 was used as 
the data acquisition software. The chromatography was performed using an Rtx-Wax 60.0 m x 0.25 
mm ID x 0.25 μm film thickness (Polyethylene Glycol - Restek, Bellefonte, PA, USA) GC column. 
Helium was used as the carrier gas with the GCMS set to a constant linear velocity of 29.1 cm/sec. 
The injector was operated in splitless mode for 5 min then switched to a 10:1 split ratio.  
The column oven was held at 40 oC  for 3 min (during desorption of the SPME fibre), then heated to 
220 oC at 4 oC /min followed by a final ramp to 250 oC at 30 oC / min and held at this temperature for 
11 min, total run time was 60 min. The interface and MS source temperatures were set at 250 oC and 
230 oC respectively. The MS was operated in electron impact mode (EI) at an ionization energy of 
70eV. 
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All analytes were analysed in full scan mode with selected VOC peaks (metabolites) integrated for 
semi-quantitative analysis utilising the IS present.  Identification of VOC compounds was made using 
the NIST 11 (National Institute of Standards and Technology) and Wiley 10 (John Wiley & Sons Inc.) 
mass spectral libraries. Peak identifications were confirmed using published retention indices 
(Umano et al., 1999), (Lee  & Shibamoto, 2000), (Acree & Arn, 2004), (El-Sayed, 2014) for wax 
(polyethylene glycol) GC columns. 
4.3 Results 
4.3.1 Non-volatile metabolites 
Colorimetric enzymatic assays were used to evaluate lactic acid and ethanol concentrations in the 
BBAN samples. Lactic acid and ethanol assays were studied for samples of control batches 1 and 2, 
Canterbury, Waikato and Balclutha. Ethanol concentration was higher (400 mg/100 ml) when the 
product was 1 day old (ST1) and decreased when storage days increased in control 1 (Table 4.1). The 
ethanol concentration was 205 mg/100 ml when the product was 4 weeks old (ST28). Similarly 
ethanol concentration in control 2 was found to be 646 mg /100 ml and 205 mg/100 ml in ST1 and 
ST28 respectively. Total lactic acid concentration in control 1 and 2 varied with different storage 
days. While total lactic acid concentrations were 230 mg/100 ml (ST1) and 373 mg/100ml (ST28) in 
control 1, it was evaluated 346 mg/100 ml (ST1) and 230 mg/100 ml (ST28) in control 2. Total lactic 
acid and ethanol content were higher in the Lot 2 products of control batches. For example, total 
lactic acid and ethanol concentrations were 635 mg/100 ml and 482 mg/100 ml in lot2 ST28 of 
control 2.  
The amount of lactic acid and ethanol were found to be higher in all other tested samples than 
control samples. Of tested samples, results obtained from control batches 1 and 2 showed better 
conformity than others. Ethanol, a primary end product of yeast fermentation, was higher in fresh 
products and decreased when storage days increased. Overall ethanol content in control samples 
were below 1% v/v. Samples collected from Canterbury and other production sites with different 
storage days contained more than 1% of ethanol which did not decrease with increasing storage 
days (Table 4.2). Samples that contained more than 1000 mg/100 ml ethanol concentration included 
Canterbury ST7 (1133 mg/100 ml), Canterbury L3 ST28 (1436 mg/100 ml), Canterbury ST28 (1077 
mg/100 ml) and Waikato ST28 (1048 mg/100 ml). 
Most the samples tested for lactic acid concentration showed that BBAN products contained higher 
percentage of L-lactic acid than D-lactic acid. However, samples of control batches such as Control 1 
ST07, Control ST07 and ST28 showed higher amount of D-lactic acid than L-lactic acid. Higher lactic 
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acid concentration was obtained from the Canterbury L1 ST21 (573 mg/100 ml) while lowest lactic 
acid content was measured from control ST07. It seemed storage days and different manufacturing 
sites did not have any influence on lactic acid content. Control 1 ST21 (541 mg/100 ml), Canterbury 
ST21 (573 mg/100 ml) and Canterbury ST28 (501 mg/100 ml) were the samples measured with 
highest amount of lactic acid content. 
Control batches produced under the laboratory condition. Production of Lactic acid and ethanol in 
the BBAN were higher in usual products than that of products produced in the laboratory 
environment. The mechanism of interaction between both yeast and LAB is not well understood. 
Table 4.1   Lactic acid and ethanol concentrations in the final product (Control batch 1 and 2) at 
different sampling times during storage. 
Control 1 Ethanol 
mg/100 ml 
Ethanol      
% (v/v) 
D-lactic acid 
mg/100 ml 
L-lactic acid 
mg/100 ml 
Total lactic 
acid mg/100 
ml 
ST 1 400 0.51 70 160 230 
ST07 329 0.42 88 44 132 
ST14 289 0.37 253 160 413 
ST28 205 0.26 255 118 373 
Control 2  
 
ST 1 646 0.82 120 226 346 
ST7 421 0.53 163 102 265 
ST28 378 0.26 151 79 230 
Lot2 ST 1 304 0.39 96 260 356 
Lot2 ST 21 581 0.74 173 368 541 
Lot 2 ST28 635 0.80 170 312 482 
ST: Storage; L: lot. 
 
 
Table 4.2    Lactic acid and ethanol concentrations in BBAN samples collected at various production 
sites. 
 
Canterbury Ethanol 
mg/100 ml 
Ethanol      
% (v/v) 
D-lactic acid 
mg/100 ml 
L-Lactic acid 
mg/100 ml 
Total lactic acid 
mg/100 ml 
140123 L1 ST7 1133 1.43 208 220 428 
140123 L1 ST21 985 1.25 244 330 573 
140123 L3 ST28 1436 1.82 168 170 338 
140107 L 2 ST14 613 0.78 127 184 311 
140107 L 1 ST28 808 1.02 130 208 338 
140306 ST7 956 1.21 26 229 255 
140306 ST28 1077 1.36 157 344 501 
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Different sites 
Waikato ST07 876 1.11 98 207 305 
Waikato ST28 1048 1.33 187 213 401 
Balclutha ST07 802 1.02 106 168 274 
Balclutha ST14 815 1.03 107 186 293 
Balclutha ST28 823 1.04 173 234 407 
4.3.2 Volatile Metabolites 
 
Analysis of metabolites in animal probiotics containing LAB and yeast is important since some 
metabolites produced by these organisms can have a positive effect in stimulating bacterial growth 
in the digestive tract and optimizing feed intake. The detection of metabolites in molasses 
fermented biological samples from mixed cultures of yeast and LAB has not been previously 
reported. The metabolite profiling study of BBAN was initially conducted using a liquid solvent 
extraction method (De Jong & Badings, 1990) as described in 4.2.2. The GCMS Chromatograms 
obtained showed that the number of peaks observed was very low, only 5 peaks were detected. 
Since this method was not considered effective, headspace analysis (HS-SPME-GC/MS) was 
investigated as an alternative using a low temperature extraction of 30 °C and an arbitrary 
incubation time of 30 min. Figure 4.1 shows a HS-SPME chromatogram for a stage 3 BBAN sample 
with many more peaks detected compared with the liquid solvent extraction trialled. 
 
 
Figure 4.1   Typical HS-SPME/GC-MS chromatograms of a stage 3 BBAN sample. 
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Peak overloading occurred for two compounds, namely ethanol and butyric acid, when sample 
volumes of 2 ml or more were used. Hence a sample volume of 1 ml was adopted to improve the 
quality of these two peak shapes by reducing the column overloading. The amount of IS added was 
also investigated with the amount added set at 20 µl or a concentration of 122.2 µl in the 9 ml vial 
solution. These initial HS-SPME extraction conditions were used as BBAN products were considered 
biologically active, meaning that higher extraction temperatures would likely produce volatiles that 
were not originally in the samples. In the resulting chromatograms detected peaks whose similarity 
match was more than 90% were considered, identified according to the NIST 2011 and Wiley 10 
mass spectral databases. These compound identities were then confirmed using published kovats 
indices for polyethylene glycol (wax) GC columns (www.pherobase.com), (www.chemspider.com), 
(www.flavornet.org), (Lee  & Shibamoto, 2000). Although chromatograms obtained, showed vastly 
more peaks were detected, 34 detected in sample (Control 1 Stage 3 Day 3) and only a subset of 
these were identified and subsequently confirmed using published kovats indices. In this example, 
31 compounds were identified with only 19 identities confirmed and about 18 compounds were 
identified as metabolites (Figure 4.2).   
 
Figure 4.2   Confirmation of metabolites using Kovats indices for sample (Control 1 S3 D3) when 
vial temperature and extraction time were 30 oC and 30 min respectively. 
 
Not satisfied that earlier assumptions concerning extraction temperatures were valid, other HS-
SPME extraction conditions were investigated to see whether more metabolites would be detected. 
The HS-SPME extraction method used by Kopsahelis et al., (2009) was trialled with some 
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modifications, 1 ml of sample was used for extractions rather than the 10 ml as described by these 
authors. Keeping all other sample parameters the same as the initial method employed but 
increasing the extraction temperature and time, (60 oC for 45 min) resulted in more volatile and 
semi-volatile metabolites being detected. This method was found to be very effective in detecting 
metabolites. For example when the BBAN sample from Canterbury (ST10) was analysed, 140 peaks 
were detected, 100 of these were identified with 72 compound identities confirmed using published 
kovats indices (Figure 4.3).  
 
Figure 4.3   Confirmation of metabolites using Kovats indices when vial temperature and 
extraction time were, 60 oC and 45 min (1 ml of sample). 
 
Of these confirmed, identified volatile compounds only a subset of these could be considered 
metabolites. In order to identify the metabolites derived solely from the yeast and LAB 
fermentation, samples containing unfermented molasses (stage 3 blank) were ran through the HS-
SPME-GC/MS method. Metabolites exclusively from the BBAN products were identified by 
comparing the unfermented molasses samples with the fermented analogues. A total of 40 different 
metabolites belonging to the chemical class of organic acids, alcohols, esters, carbonyl compounds, 
sulphur compounds and miscellaneous compound were detected (Table 4.3). 
In the current study BBAN samples were collected from different production sites (Canterbury, 
Waikato and Balclutha) at many stages of production (Stage 1, 2 and 3 and storage days). An initial 
study looking at the stages of production of the Canterbury site and utilised the initial HS-SPME/GC-
MS extraction method of 30 °C for 30 min. From this study a smaller list of 32 metabolites was 
obtained (Appendix A and B). A second study then looked at a total 19 BBAN samples of final 
product collected at Canterbury (13 samples), Waikato (3 samples) and Balclutha (3 samples) 
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production sites with different storage days, were analysed using the HS-SPME/GC-MS methods 
described in 4.2.2.2 as this was found to be the most effective in the extraction of volatile 
compounds from these biological samples. Metabolites were profiled in these samples using the 40 
identified metabolites listed in Table 4.3. 
 
Table 4.3   Volatile metabolites from BBAN isolated by the SPME/GC-MS, categorized according to 
chemical class. 
Chemical Metabolite KI    Chemical Metabolite KI  
Class     published   Class   published 
Ester Ethyl formate 848  Alcohols Ethanol  929 
 Ethyl acetate  886   1-propanol 1040 
 Ethyl propanoate 950   1-Butanol  1145 
 Ethyl butyrate 1028   Isoamyl alcohol 1205 
 Ethyl hexanoate 1220   1-hexanol 1360 
 Butyl acetate 1105   3-octanol 1406 
 Isoamyl acetate 1117   1-Octanol 1553 
 Isobutyl butyrate 1152   2-pentanol 1130 
 Isoamyl butyrate 1267   Isobutanol 1108 
 Phenyl butyrate             -   Eugenol 2161 
 Methyl salicylate 1786   (Z)-isoeugenol 2298 
 Phenyethylbutyrate 1930   Menthol 1626 
      Benzyl alcohol 1865 
Organic Acetic acid 1450   Phenyl ethanol  1925 
 acid Butyric acid 1619   Phenol 1951 
 Octanoic acid  2083   p-Ethylguaiacol 2048 
 Hexanoic acid 1829   p-Cresol 2077 
      4-ethyl-phenol 2195 
Carbonyl  Diacetyl 977     
compounds (3E)-3-penten-2one 1128  Sulphur  Dimethyl sulfide  844 
 gamma-nonalactone 2024  compounds Methionol 1738 
        
     Miscellaneous  2,5-dimethyl- furan  943 
     compound   
 
 (http://www.chemspider.com, http://www.flavornet.org, http://www.pherobase.org,                                          
(Lee  & Shibamoto, 2000)) 
 
The volatile compounds from both studies were tentatively quantified using the technique described 
by Kopsahelis et al., (2009) where the peak areas of the compounds of interest were divided by the 
peak area of the IS then multiplying this ratio by the initial concentration of the IS (expressed as 
µg/l). Concentrations reported in Appendix B, C and Table 4.4 are pseudo concentrations based 
solely on their comparison to the concentration of the IS. In SPME analyses such concentrations are 
indicative as the only way to determine an accurate concentration using this extraction technique is 
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to use internal standards that are chemically similar to each of the analytes of interest such as 
deuterated analogues. From the 42 metabolite compounds detected in the second study (Appendix 
D), 10 were selected as the major metabolites and these were used to compare BBAN samples from 
different sites (Table 4.4). All peak areas were obtained from the full scan chromatograph using the 
total ion current (TIC).  
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Table 4.4    Relative amounts (µg/l) of major volatile compounds identified by HS-SPME/GC-MS from different BBAN samples 
Metabolite KI RT Bal Waik Ctrl1 140123 140306 Ctrl 2 Ctrl 1 Balc Waik 140107 
Compounds published (min) ST7 ST7 ST7  ST7 L2 ST7  ST7 ST 14 ST14 ST14 L2 ST14 
Ethyl acetate  886 5.72 51.4 96.3 26.6 135.9 75.7 56.5 43.7 100.6 82.1 146.5 
Ethanol  929 6.84 1073.7 1212.0 969.4 1530.7 966.3 1215.5 1137.1 1429.6 1294.3 1031.7 
Ethyl butyrate 1028 9.49 382.7 551.0 375.5 496.0 428.1 417.3 501.0 469.7 656.2 571.9 
Isobutanol 1108 11.60 40.3 50.2 23.0 40.4 33.3 30.8 28.6 32.3 36.5 38.4 
Isoamyl acetate 1117 12.20 16.8 38.1 9.8 31.2 20.5 20.6 14.0 14.7 43.4 30.3 
Isoamyl alcohol 1205 15.48 372.7 530.2 266.3 485.8 317.6 396.6 324.4 421.0 591.2 376.4 
Acetic acid  1450 23.56 285.1 230.7 251.5 406.2 320.2 315.0 336.4 369.2 109.6 458.6 
Butyric acid  1619 29.03 3132.6 2179.5 3195.2 2781.4 2797.6 3304.2 3527.0 3327.7 2517.3 2610.5 
Phenylethyl Alcohol  1925 37.29 184.9 268.4 104.5 340.5 152.8 194.3 142.9 215.0 325.7 168.8 
Phenol 1951 39.57 114.6 6.4 124.3 122.5 90.4 115.6 167.1 127.5 6.1 68.1 
             
Metabolite  KI  RT Ctrl 2   140107 140306 Ctrl1  Ctrl 2  Waik  140123 Balc  140107   
Compounds published (min) ST 28 ST28 ST28 ST28 L2 ST28 ST28 L3  ST28 ST28  ST42   
Ethyl acetate  886 5.72 92.4 192.3 134.1 64.7 96.3 219.5 433.6 115.7 228.6  
Ethanol  929 6.84 949.1 1084.0 1069.3 913.5 850.7 1657.1 1230.0 1177.8 975.2  
Ethyl butyrate 1028 9.49 506.1 612.7 629.1 476.9 464.2 798.9 73.4 555.4 682.3  
Isobutanol 1108 11.60 32.8 33.4 39.5 31.7 12.5 47.8 92.7 40.7 29.3  
Isoamyl acetate 1117 12.20 21.9 32.8 32.4 13.6 17.8 75.4 120.7 25.6 38.2  
Isoamyl alcohol 1205 15.48 312.7 390.5 357.0 267.6 170.7 677.0 781.7 380.3 341.1  
Acetic acid  1450 23.56 289.1 445.5 392.5 293.5 466.4 361.5 361.0 401.6 458.1  
Butyric acid  1619 29.03 2738.0 2568.1 3017.4 3074.5 2812.0 2617.6 229.2 3221.1 2331.3  
Phenylethyl Alcohol  1925 37.29 156.9 174.5 183.6 115.3 58.6 364.5 408.4 197.5 157.8  
Phenol 1951 39.57 93.5 72.5 112.5 137.2 111.1 8.7 9.6 117.3 66.7  
 
RT: Retention Time; Waik: Waikato; Balc: Balclutha; Ctr1: Control 1; Ctr2: Control 2; L1, L2 and L3: Lots; µg/l Rel IS: Is a comparison to the concentration of the internal 
standard in the vial (122.2 µg/l) corrected for the dilution factor (X9); Amounts stated are indicative only and are not the true concentration (http://www.flavornet.org, 
http://www.pherobase.org, http://www.chemspider.com, (Umano et al., 1999),(Lee  & Shibamoto, 2000)). 
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4.3.2.1 1st Study results 
An initial study mainly focused on looking at the stages of production of the Canterbury site. As we 
discussed in 3.2.2 production cycle consisted three steps. Sugar was used as a substrate for yeast 
and LAB fermentation in stage 1 of production and very few volatile metabolites were detected. 
Ethanol (1987.5 µg/l) and isoamyl alcohol (1288.3 µg/l) were major end products in the yeast 
fermentation of stage 1 (S1 D1 Y) followed by isobutanol (176.2 µg/l), ethyl acetate (87 µg/l), 
diacetyl and phenyl ethanol (Appendix C). 
However, the metabolite profile was different in the LAB fermentation (S1 D1 L) where acetic acid 
and diacetyl were the major metabolites detected. The use of molasses as a substrate and an 
increasing number of fermentation days may have been attributable in the detection of a larger 
number of volatile metabolites in the stage 2 and 3 fermented products (S2 D3 Y, S2 D3 L and S3 D3 - 
Appendix C). The number of metabolites and their relative amounts increased in stage 2 where 
molasses was used as a substrate. This was seen in the yeast samples from the stage 2 fermentation 
where butyric acid, acetic acid, dimethyl sulphide, ethyl butyrate, isoamyl butyrate, and phenol were 
found in addition to those identified in stage 1. Moreover, metabolites already identified in stage 1 
were detected in higher quantities i.e. ethanol (3364.9 µg/l), isoamyl alcohol (3121.1 µg/l), ethyl 
acetate (615.3 µg/l) and isobutanol (327.7 µg/l). 
Butyric acid (4154.6 µg/l) was detected in higher quantity in the stage 2 LAB fermented product (S2 
D3 L) followed by acetic acid (103.8 µg/l), 1-butanol (185 µg/l), ethanol (60.4 µg/l) and phenol (53.2 
µg/l). The largest number of metabolites were detected in the stage 3 mixed fermentation samples 
however quantities seen varied compared with samples from yeast or LAB alone. This showed that 
the metabolites produced in stage 3 mixed fermentation were not simply a summation of the 
quantities found in the single yeast and LAB stage 2 ferments. Here only acetic acid and ethyl 
butyrate exhibited quantities higher in stage 3 than stage 2 (Appendix C).  Thus, it appears that the 
number of brewing days, the formulation and culture types influence metabolite production in the 
BBAN products.  
4.3.2.2 Second Study results 
A second study was undertaken to determine what differences if any, there were in the volatiles 
metabolites found in BBAN samples manufactured in Canterbury, Waikato and Balcultha at the 
various stages of production. To provide focus the 10 most abundant volatile metabolite compounds 
were selected for examination in this second study (Table 4.4). These were organic acids (acetic acid 
and butyric acid), alcohols (ethanol, isobutanol, isoamyl alcohol and phenylethyl alcohol), esters 
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(ethyl acetate, ethyl butyrate and isoamyl acetate) and phenol. It is important to note here that 
although these metabolites were selected due to their abundance, the degree to which they were 
detected was influenced by the SPME fibre type and the extraction conditions used.  The abundance 
of a compound in the headspace of a vial is due in part to the boiling point/vapour pressure and 
polarity of that compound at the extraction temperature. The solid phases of the SPME fibre 
preferentially adsorb compounds present in the headspace based on the selectivity of their solid 
phase chemistry, with the DVB/CAR/PDMS fibre used best suited to the detection of a wide variety 
of compounds.  
Two control batches along with production stage 3 samples taken from Canterbury, Waikato and 
Balclutha (varying storage times, 7-28 days) were analysed for volatile metabolites (Appendix D). 
Also included in this 19 sample study were two BBAN variant products from Canterbury, namely 
batch 140123 L3 ST28 (lot 3, 4 weeks production) produced using a starter culture which was more 
than 10 days old, and sample batch 140107 ST42 with an extended storage time of 6 weeks. These 
were analysed according to the HS-SPME extraction method described in section 4.2.2.2. 
Butyric acid was found to be the major volatile component detected in all the BBAN analysed 
followed by ethanol, ethyl butyrate, isoamyl alcohol and acetic acid.  At the end of 4 weeks of 
storage (ST28) more than 3000 µg/l of butyric acid was detected in Control 1, Balclutha and 
Canterbury (batch no: 140306). However the overall butyric acid content in all tested samples, 
irrespective of storage day, ranged between 2331-3527 µg/l except for 140123 L3 ST28 in which only 
229.2 µg/l was detected. The highest concentration of butyric acid (3527.0 µg/l) was detected in 
Control 1 ST14 at 2 weeks storage.  
The highest ethanol concentration (1657.1 µg/l) was detected in the Waikato sample (ST28) with 4 
weeks of storage while the lowest ethanol concentration (850.7 µg/l) was measured in Lot 2 of 
control 2 at 4 weeks of storage. In addition, 798.9 µg/l of ethyl butyrate (Waikato ST28, 4 weeks 
storage) and 73.4 µg/l (Canterbury batch 140123 L3 ST28) were found to be the highest and lowest 
concentrations respectively.  Isoamyl alcohol was found in its largest concentration (781.7 µg/l) in 
Canterbury sample 140123 L3 ST28 while the minimum concentration (170.7 µg/l) was found in 
Canterbury control 2 L2 ST28 sample at 28 days of storage. A maximum concentration of 408.4 µg/l 
phenyl ethanol was found in Canterbury sample 140123 L3 ST28 while the lowest concentration 
(58.6 µg/l) was detected in lot 2 of control 2 ST28. While lowest phenol concentrations (6.1-8.7 µg/l) 
were found in all three Waikato samples analysed, highest phenol concentration (167.1 µg/L) was 
measured in control 1 ST14 (2 weeks of storage). Notably, when compared with the other samples in 
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this study, those from Waikato exhibited high concentrations of isoamyl alcohol and phenyl ethanol 
and showed the lowest concentration of phenol.  
More than 400 µg/l of Acetic acid were found in samples analysed from the Canterbury site such as 
batch: 140123 ST7, batch: 140107 Lot 2 ST14, batch: 140107 ST28, Control 2 lot 2 ST28 and batch: 
140107 ST42 with 6 weeks storage.  
It is worth noting that metabolites produced from BBAN under extended storage conditions (6 
weeks storage) did not significantly differ from those produced under shorter storage conditions. 
The ethanol 975.2 µg/l, butyric acid 2331.3 µg/l and acetic acid 458.1 µg/l found in sample 140107 
ST42 is consistent with the number of viable microbial counts present in the product after 6 weeks 
of production. 
However, higher amount of alcohols, esters and lower amount of organic acids were detected in the 
product prepared from the several days old starter culture. Lower concentration of butyric acid 
(229.2 µg/L) and ethyl butyrate (73.4 µg/L); higher concentration of isoamyl alcohol (781.7 µg/L), 
phenyl ethyl alcohol (408.4 µg/L), isobutanol (92.7 µg/L), isoamyl acetate (120.7 µg/L) and ethyl 
acetate (433.6 µg/L) was detected in L3. Moreover, 1-propanol was detected only in L3 and which 
was not detected in any other samples. Concentration of major metabolites such as ethanol and 
butyric acid detected in single culture (stage 2) were higher than compounds detected in mixed 
culture. 
 
4.4 Discussion 
Metabolite profiling studies between dairy yeasts and LAB strains during milk fermentation (Álvarez-
Martín et al., 2008) and molasses fermentation by combination of LAB and yeast strains at different 
temperature have been previously reported (Kopsahelis et al., 2009). However, to the best of our 
knowledge this is the first case to report the study of detecting metabolic compounds in molasses 
fermented product having mixed culture of yeast and LAB. The metabolic composition of BBAN may 
provide a window for elucidating the health benefits using probiotics.  Viability results showed that 
LAB population were higher than MSL in BBAN products with different storage days. Yeast 
population found to be higher at the first week of storage and decreased towards the end of expiry 
day.  Lactic acid is a major end product of sugar fermentation by LAB whereas ethanol being the 
major end product of yeast fermentation.  
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Growth of LAB and yeast can be considered as coupled process with lactic acid and ethanol 
production. Therefore it can be inferred that the lactic acid can be higher and maintained with 
different storage days, while ethanol decreased when storage increased. However, results obtained 
from lactic acid and ethanol assays did not behave according to cell densities. Only control batches 1 
and 2 showed better conformity for ethanol concentration than other tested batches. Ethanol, a 
primary end product of yeast, was higher in the single culture and decreased when storage days 
increased in the final product. However, various amounts of lactic acid concentration was measured 
in tested samples. Lactic acid was ranged 132-573 mg/100ml amongst different batches. Though the 
exact mechanism is not understood for this variation, interaction between LAB and yeast may 
influence the amounts of metabolites production. For example, positive interaction by yeast have 
been reported to stimulate LAB through the production of CO2, pyruvate, propionate and succinate 
(Leroy & Pidoux, 1993). Composition of growth media may influence the end products of 
fermentation. For an example, lactose is main energy source for LAB in the milk fermentation. 
Molasses, contains 75% sucrose and 25% glucose & fructoseis utilized as energy source for microbial 
fermentation (Olbrich, 2006). Therefore, organic acid profile of BBAN is influenced by molasses and 
combination of LAB and yeast. It should be noted that though growth of LAB and lactic acid 
production are closely associated processes, sometimes lactic acid production can be maintained by 
non-growing cells under undefined stress conditions (van de Guchte et al., 2002). 
Both volatile and non-volatile study indicated that important antimicrobial compounds such as lactic 
acid, ethanol and other alcoholic compounds, acetic acid, butyric acid, diacetyl, and etc. were 
identified in the BBAN. It has been demonstrated that metabolites such as organic acids (lactic acid 
and acetic acid), ethanol, diacetyl, H202, acetaldehyde and bacteriocin have been responsible for 
antimicrobial activities by probiotic action (Brki et al., 1995; Vandenbergh, 1993). 
Beneficial effects by LAB and their metabolites included antimicrobial action against pathogenic 
organisms, prevention of food spoilage and the extension of the shelf-life of food. Additionally, these 
metabolites have a number of roles including providing nutritional substances, enhancing immunity 
response by removing toxins and stimulating activity of bile salt hydrolase to transfer cholesterol for 
therapeutics absorption (Fuller, 1989; Heyman, 2000; Holzapfel et al., 1998). For example, liquid 
metabolite combinations produced by L. plantarum improved growth performance, reduced the 
incidence of diarrhoea and increased the population of gut LAB and faecal SCFA when fed to post-
weaned piglets (Thu  et al., 2011). 
Organic acids detected in the BBAN included mainly lactic acid, acetic acid, butyric acid, octanoic acid 
and hexanoic acid. Lactic acid and acetic acid are the most important and best characterized 
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antimicrobial against pathogenic and spoilage organisms. Lactic acid, produced by probiotic LAB 
functions as a natural antimicrobial and has been demonstrated to inhibit the growth of gram 
negative species of the bacterial families such as Enterobacteriaceae and Pseudomonadaceae  
(Doores, 1993). Furthermore, lactic acid has been recognized as a biopreservative in natural 
fermented products (Ray & Sandine, 1992). In vitro studies indicated that production of lactic acid by 
Lactobacillus species inhibited growth of C. jejuni and reduced colonization by disrupting membrane 
of C. jejuni in broiler chickens (Neal-McKinney et al., 2012). Acetic acid exhibits antagonistic effect 
against yeast species and the inhibitory effects by lactic acid and acetic acid is caused by the 
reduction of intracellular pH and dissipation of membrane potential (Kashket, 1987).  
Octanoic acid/Caprylic acid (fatty acids) have bactericidal and anti- fungal (notably against Candida 
species) properties. Caprylic acid and its monoglyceride, monocaprylin, have shown effectiveness 
against major bovine mastitis pathogens Strep. agalactiae, Strep. dysgalactiae, Strep. uberis, S. 
aureus, and E. coli (Nair et al., 2005).  Hexanoic acid /caproic acid, straight-chain fatty acid provides 
variety of flavours such as butter, milk, cream, strawberry, bread, beer and nut and is normally 
found in beer to contribute caprylic flavour (Clapperton, 1978). 
 Acetic, propionic, isobutyric, butyric, isovaleric and valeric acid have been categorized into SCFA 
which are mostly absorbed in the large intestine and provide energy to the host animal (Franklin et 
al., 2002). Butyric acid, the metabolite more abundantly found in BBAN, than other metabolites is 
normally produced within the intestinal lumen and exerts a wide variety of effects on intestinal 
function (Hamer et al., 2008). Multiple functions provided by butyric acid included well documented 
anti-inflammatory effects, reinforcement of colonic defence barrier by producing mucin, and 
antimicrobial peptides and decreased intestinal epithelial permeability by increasing the expression 
of tight junction proteins (Breuer et al., 1997).  Anti-inflammatory activities coupled with a 
strengthening of mucosal barrier integrity make butyric acid of potential therapeutic value against 
IBD (Van Immerseel et al., 2010). 
Alcohols are largest group of chemical class detected in the BBAN, followed by ester, organic acids, 
carbonyl compounds and miscellaneous compounds. There were more than 15 different alcohols in 
varying amounts detected in the BBAN. It has been reported that animals fed with metabolite 
combinations could yield better performance due to presence of organic acids, ethanol, bacteriocins, 
H2O2 and vitamins in the metabolite combinations (Desouky & Ibrahim, 2009; Foo et al., 2005). 
Ethanol was major alcohol type identified in the product. Apart from ethanol, major alcohol type 
included phenylethyl alcohol, phenol, isoamyl alcohol and isobutanol. Ethanol and CO2 are the major 
end products of yeast fermentation and this causes inhibitory effects to many undesirable 
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microorganisms (Ferreira & Viljoen, 2003). Phenyl ethyl alcohol (PEA) is an aromatic alcohol with a 
rose-like odour mostly produced by yeasts from aromatic amino acid metabolism (Naz et al., 2013). 
The production of PEA has shown the ability to inhibit the growth of gram-negative bacteria, such as 
Salmonella, Escherichia, Shigella, Aerobacter, Klebsiella, Pseudomonas and Proteus (Lilley & Brewer, 
1953).  Higher alcohols (fusel alcohol) are most abundant organoleptic compounds present in beer. 
These higher alcohols produced in the Lager beer (Table 4.5) were also detected in BBAN including 
n-propanol (sweet), isobutanol (solvent), isoamyl alcohol (banana), amyl alcohol (Solvent) and 2-
phenylethanol (roses).   
Table 4.5 Higher alcohols present in Lager Beer Pires et al. (2014) 
Compound Threshold  (mg/l) Concentration range (mg/l) Aroma impression 
n-propanol 600 4-17 Alcohol, sweet 
isobutanol 100 4-57 solvent 
Isoamyl alcohol 50-65 25-123 Alcoholic, banana 
Amyl alcohol 50-70 7-34 Alcoholic, solvent 
2-phenylethanol 40 5-102 roses 
 
Second largest group of chemical class identified in the probiotic formulation is ester and almost 13 
different esters were detected in the product. Esters are formed in a reaction between alcohols and 
organic acids (Engels  & Visser 1994). Therefore, with a larger number of different alcohols and 
organic acids in BBAN, there is considerable potential for the formation of wide range of esters. Ethyl 
esters are straight chain fatty acids mostly responsible for fruity aroma of fermented alcoholic 
beverages (Sumby et al., 2010). Amongst various ethyl ester groups, ethyl acetate (fruity, balsamic, 
solvent-like aroma) and ethyl butyrate (floral, fruity, strawberry, sweet) were largely found in BBAN, 
followed by ethyl formate, ethyl propanate and ethyl hexanoate (fruity, strawberry, green apple and 
anise aroma). Most of these esters are important aromatic yeast metabolites found in beer  and 
wine including ethyl butyrate, ethyl hexanoate, ethyl octanoate, ethyl acetate, isoamyl acetate 
(banana aroma), isobutyl acetate (fruity aroma), phenyl ethyl acetate (roses and honey aroma), and 
ethyl octanoate (Pires et al., 2014; Sumby et al., 2010). Esters, are found in beer only in trace 
amounts and have a very low odour threshold. However, if overproduced, they can negatively affect 
the beer with a bitter, over fruity taste (Pires et al., 2014).Isobutyl butyrate, isoamyl butyrate and 
phenyl ethyl butyrate   have been widely used as food grade flavouring agents . 
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Diacetyl (2, 3-Butanedione) is another important metabolites with characteristic buttery aroma 
produced by LAB detected in BBAN that have shown antimicrobial spectrum against gram-negative, 
gram-positive and yeast (Suskovic et al., 2010).  
Dimethyl sulphide and methionol are Volatile sulphur flavour compounds (VSFC) found in BBAN in 
small amounts. These VSFC are commonly found in many foods and beverages as aroma compounds 
with low detection thresholds (Seow et al., 2010). Eugenol and (Z)-isoeugenol are type of Guaiacol 
which is a naturally occurring organic compound. Eugenol exhibit antibacterial, antifungal, anti-
inflammatory activity, insecticidal and antioxidant properties, and are used traditionally as flavouring 
agent and antimicrobial material in food (Huang et al., 2002).  
In addition, metabolites like (3E)-3-penten-2-one, 2, 5-dimethyl- furan (used as biofuel (Zu et al., 
2014) and gamma-Amylbutyrolactone (used as cosmetic, flavour and fragrance agents-
(www.thegoodscentscompany.com)) detected in the BBAN. Although these compounds are not 
usually found in the food products that raised safety concerns. However, the relative amounts of 
these metabolites found in trace amounts in the BBAN. 
Although the product was not investigated for gas content, it is obvious the product contains 
considerable amount of CO2 which exhibits antimicrobial activity especially, anti-fungal activity 
because of its ability to accumulate in the membrane lipid bilayer resulting in dysfunction in 
permeability (Lindgren  et al., 1990). Combination of pH reduction and conversion of sugars to 
organic acids by LAB plus production of CO2 and alcohol by yeast have inhibitory effect on many 
undesirable microorganisms in the fermented product (Ferreira & Viljoen, 2003). 
Finally, metabolites such as lactic acid, ethanol, acetic acid, butyric acid, diacetyl with antimicrobial 
properties and various aromatic ester compounds were detected in the product. The production of 
organic acids and other metabolites varied with different storage days of the same product and 
products from different production sites. The variation in metabolite concentration amongst various 
storage days cannot be correlated with viable cell counts of LAB and yeast and this variation did not 
show clear tendency. The relative concentration we discussed above is not the true concentration, it 
is indicative value only. Detecting true concentration by quantification method is the next step of 
this study and which would validate the metabolite concentration in the BBAN. 
4.5 Conclusions 
Ethanol and lactic assays confirmed that the product contained considerable amount of lactic acid 
and ethanol in BBAN. HS-SPME/GCMS analysis was used to detect the semi-volatile and volatile 
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metabolites in the BBAN. Several chemical groups of volatile metabolites in varying quantities were 
identified and alcohols were the largest group of chemical class detected in the BBAN, followed by 
ester, organic acids, carbonyl compounds, sulphur compounds and miscellaneous compounds. Lactic 
acid, ethanol and butyric acid were primary metabolites detected in higher quantities in BBAN 
formulation. Lactic acid, acetic acid, ethanol, butyric acid, diacetyl were the important metabolites 
identified with antimicrobial properties. 
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Chapter 5 
Quality assurance (QA) system to produce the product 
5.1 Introduction 
In recent years, the use of fermented liquid feed in animal nutrition has significantly been increased 
because of their relative advantages over other forms of delivery. The aim of reducing the use of 
antibiotics and the availability of liquid animal feed for cheaper prices may be attributable for 
increased usage (Canibe & Jensen, 2012). LAB are naturally a core part of the gut microbiota and 
probiotics containing LAB have shown ability to adhere to and colonise in the host gut (Spencer & 
Chesson, 1994) and improve animal health (Cross, 2002). Fermented liquid feed consisting of LAB 
have, through their beneficial effects, been shown to improve the animal health (Plumed-Ferrer & 
von Wright, 2009). Yeast based products have been fed to animals for more than hundred years.  S. 
boulardii is an important yeast species employed in probiotics and it has been demonstrated that 
the probiotic contains live yeast (S. boulardii) preparations can stimulate enzyme activities and 
active against various pathogens (Czerucka & Rampal, 2002). 
Molasses as animal feed has been used for many years. Since molasses contains about 50% sugars in 
the form of sucrose, glucose and fructose, which give readily available energy, it is directly fed to 
ruminants, cattle and sheep in many different ways or used in silage formation (Cleasby, 1963).  
BBAN is molasses fermented animal probiotic formulation consisting of multi-species and multi-
strains of LAB and yeast strains. Production of BBAN involved 3 steps fermentation and quality of 
each step is dependent on other steps of fermentation. This chapter explains how the BBAN satisfy 
the QA parameters.  
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5.2 QA during manufacturing processes  
QA is applied to products to verify whether it meet specifications and requirements, and during 
manufacturing-production run by validating lot samples meet specified quality parameters. In our 
study we analysed more than 300 BBAN samples belonged to 25 batches from Canterbury 
production site. Products at many stages of production and during storage were investigated for 
microbiological quality testing, safety and metabolic compounds. Samples of final product from 
Waikato and Balclutha; Samples with extended storage and products from several days old starter 
culture were also analysed. Intensive sampling (monitoring every day until its expiry day) was done 
for first 3 batches and rest of the batches were sampled at the end of different stages and weekly 
during storage period.  
Number of forms (BBQA01 to BBQA04) with a variety of information was prepared for data entry 
purposes (Appendix E1-E4). The information in the forms were useful to assess the QA parameters 
for the product. Generally information included sample ID, starting day of starter culture, day of 
starter culture transferred to molasses fermentation, mixed fermentation day, agar plate 
preparation day in the laboratory, pH reading, microbial counts and detection of metabolite details. 
In addition, information on product testing for various foodborne pathogens such as E. coli, 
Staphylococcus, Coliform, Listeria and Salmonella was included. 
Sugar in stage 1, and molasses in stage 2 and 3 were used as growth media and the density of these 
media was maintained as 5% w/v. LAB population in stage 1 and 2 struggled to establish and it 
reached maximum in mixed fermentation. Cell densities (7.67 log CFU/ml) and organic acid 
production in stage 1 was relatively lower than in stage 2. However, due to the influence of 
molasses, the cell counts (9.3 log CFU/ml) and number of metabolites was found higher than stage 2. 
LAB population in stage 1, 2 and 3 were significantly different from each other. However, cell 
densities in mixed fermentation did not differ with final product at different storage days.  
Yeast cell densities increased up to 1010 log CFU/ml at the end of stage 1 and maintained higher in 
the stage 2. Similar to LAB metabolites, the number and relative concentration of yeast metabolites 
was found to be higher in stage 2 than in stage 1. However, when the mixed fermentation started 
the viable counts of yeast tended to decrease. When LAB and yeast are found in a single product, 
growth requirement for these microbes are different and there can be negative and positive 
interaction between them. 
 
The following factors observed in this study confirmed that the influence of LAB on yeast growth: 
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a) Ethanol production in the single culture is much more than in the co-culture. 
b) The growth of yeast tended to decrease in the mixed culture relative to single culture. 
Weak organic acids produced by LAB have been shown to inhibit yeast growth without interfering 
with development of LAB population in the liquid feed (Plumed-Ferrer & von Wright, 2011). On the 
other hand, there are reports of stimulating effect of LAB on yeast growth especially because of 
lactic acid and acetic acid production (Thomas et al., 2002). The temperature requirement for the 
growth of LAB and yeast are 37 oC and 25 oC respectively. However, the temperature, in the mixed 
culture has been set to 37 oC. The temperature rise in the mixed culture may affect the viability of 
the yeast cells. Moreover, LAB is mostly anaerobic or sometimes facultative in nature. Therefore 
during mixed fermentation and storage period product is maintained in anaerobic condition. This is 
unfavourable for yeast species which while not strictly aerobic, thrive more in the presence of 
oxygen. Therefore these factors combined together may retard yeast growth in mixed culture and 
final product. Obviously, this is a question of microbial trade-off. Hence, BBAN has been designed to 
get more benefits from LAB, Increasing conditions favourable for yeast growth would affect the LAB 
population in the co-culture.  
Plate count method, we used for enumeration of viable counts in this study has some disadvantages 
like time consuming and results may be biased by poor viability or low cell densities. Currently, there 
are numerous modern and rapid methods including Solid-phase cytometry (SPC), polymerase chain 
reaction (PCR) etc. are in practice to assess microbial counts accurately. When SPC and traditional 
plate count were used to enumerate S. boulardii in several probiotic products, cell counts was 
significantly higher in SPC than plate count method. In addition, SPC quantified all the viable yeasts 
whereas plate count only enumerated viable culturalable yeast population in the products (Vanhee 
et al., 2010). 
Study of product with extended storage and production of different lots from the same starter 
revealed different quality aspects. Products produced using old starter contained more alcohol 
based metabolites in the final product when compared with products produced using fresh starter 
culture whereas Product quality was higher with extended storage than the product produced using 
several days old starter culture. 
5.3 Assessing BBAN for the QA criteria 
BBAN is discussed under following quality control criteria.  
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5.3.1 Formulation (vehicle) 
Probiotics are available in the form of powder, capsule, tablets and liquid. Viability of the probiotics 
in the form of powder and pellets are more affected than liquid fermented probiotics since pelleting 
and extrusion process require high temperature and pressure (Ananta et al., 2004; Champagne et al., 
2011). Powdered and semi-solid products may heavily be subjected to processing techniques such as 
spray drying, freeze drying and vacuum drying. During processing, these drying processes may affect 
the viability of the product by applying various stresses on the product and also some dried products 
may contain dissolved oxygen which is toxic to probiotic bacteria (Korbekandi et al., 2011)). In recent 
years, the use of fermented liquid feed in animal nutrition has significantly been increased. Some of 
the problems associated with liquid probiotics are short term shelf-life and maintaining the storage 
conditions which is usually done by refrigeration. BBAN is fresh and liquid probiotics which does not 
need any special storage requirement and can be stored at normal environmental conditions. BBAN 
contains multi species and multi strain of LAB and yeast. Reduction of pH and production of lactic 
acid, acetic acid and ethanol prevents growth of foodborne pathogens and spoilage organisms in a 
fermented liquid feed (van Winsen et al., 2001). Molasses, which are rich in nutrients and cost 
effective energy source, have long been used in livestock feeds. Probiotics supplemented by LAB and 
yeast strains in molasses fermentation ensure the health benefits to the target animals. 
5.3.2 Combination  
Probiotics containing several different species (multi-species probiotics) or various strains of one 
species (multi-strains probiotics) have been demonstrated more effective than that of using mono-
strain probiotics (Timmerman, 2004). Using multi-species and multi-strain probiotic products cover a 
broad spectrum and by their synergistic effect increases probiotic functionality and efficacy. When 
different probiotic formulations were tested in treating antibiotic-associated diarrhoea in children, it 
was found that probiotics containing lactobacilli and bifidobacteria (multi-species) were more 
effective than that of preparations with mono-strain (Timmerman, 2004). Likewise, Lema et al. 
(2001) demonstrated multi-species of lactobacilli showed higher rate of effectiveness in reducing E. 
coli shedding in sheep. On the other hand, studies suggested that use of multi-strain preparation 
effectively improved growth performance, particularly mortality in broiler chickens (Jin et al., 2000; 
Timmerman, 2004). Since BBAN is a multi-species and multi strains product, the functionality of this 
product can be more effective and consistent. 
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5.3.3 Viability  
Viability is one of the important criterion for quality assurance of probiotic products. To maintain 
functionality of the probiotic product, sufficient number of viable counts should be consistently 
maintained throughout their shelf-life of the product. Composition of most of the commercially 
available probiotics do not meet a quality standard because of having inconsistent variability (Fasoli 
et al., 2003). As a result, there have been controversy over the functionality and efficiency of the 
product. Viability has been estimated by conventional plate count method in which colonies were 
grown on a selective growth medium. In recent years, several rapid and efficient methods are used 
to enumerate viable counts since conventional methods are considered time consuming and 
underestimation of true viable counts.  
In our study we analysed 25 batches of BBAN (more than 300 samples) until its shelf-life (one 
month) and tested for microbiological quality and safety using conventional method. Higher number 
of samples and cost involved in using modern rapid methods limited us to use conventional method 
in our laboratory. However, results obtained from different batches and changes in the viable counts 
at many stages of production were consistent. 
Mean viable counts of all batches analysed during different month of study has been presented in 
Table 5.1. The results indicated the viability of the LAB was not affected when the product was at its 
end of shelf-life and the average viable counts varied between 10.7 ± 0.08 and 11.3 ± 0.00. Monthly 
analysis of viability of the LAB were not significantly different. Therefore, the BBAN contains LAB 
viable counts that is more than MSL (106 CFU/ml) and recommended level in some developed 
countries (109 CFU/dose in Canada). 
Table 5.1   Viable counts of BBAN for quality testing on monthly basis 
Month of 
production 
No. of 
batches 
Average Lb counts 
(log CFU /ml) 
Average yeast  counts 
(log CFU /ml) 
Day 7 Day 28 Day 7 Day 28 
August 2013 4 9.8 ± 0.33 10.7 ± 0.08 6.4 ± 0.27 5.4 ± 0.35 
September 2013 3 10.9 ± 0.05 10.8 ± 0.09 5.9 ± 0.41 5.2 ± 0.20 
October 2013 3  Contamination. sampling stopped 
November 2013 6 11.4 ± 0.18 11.6 ± 0.04 6.4 ± 0.73 5.6 ± 0.37 
December 2013 1 11.7 ± 0.00 11.4 ± 0.00 7.6 ± 0.00 6.0 ± 0.00 
January 2014 4 11.5 ± 0.08 11.6 ± 0.14 4.7 ± 0.13 4.8 ± 0.41 
February 2014 4 10.7 ± 0.80 11.4 ± 0.13 5.6 ± 0.54 5.2 ± 0.33  
March 2014 1 11.3 ± 0.00 11.3 ± 0.00 5.1±  0.00 5.0 ± 0.00 
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Several studies revealed that the use of multi-species and multi-strain probiotic formulations have 
been more effective than using mono-strain (Timmerman, 2004). BBAN preparations contain 
different species and strains of LAB and yeast. The viable yeast population was higher at early stages 
of production and when the storage days increased the yeast population tended to decrease. On the 
whole, the viable yeast counts were just below the MSL at the end of shelf-life. Yeast population in 
the single culture goes up to 1010 CFU/ml and the population started to decrease when it is mixed 
with LAB culture. Both positive and negative interactions between LAB and yeast have been 
reported on each other. It is likely that the strong influence of LAB (especially, low pH) on the co-
culture may inhibit the growth of the yeast in the BBAN. Moreover, yeast cells are inoculated at 25 
oC when it is grown in the single culture. But, the temperature of mixed culture rises up to 35 oC 
which is not favourable for yeast growth. However, it is revealed that the health benefits from yeast 
culture is not necessarily limited to the viable culturable yeasts and viable non-culturable S. boulardii 
which cannot be enumerated in plate count method have also shown probiotic effects (Vanhee  et 
al., 2010). Apart from this, end products of fermentation such as low pH from LAB fermentation and 
the alcohol and CO2 produced by the yeasts in combination is responsible to inhibit many 
undesirable microorganisms (Ferreira & Viljoen, 2003). 
BBAN production across different production sites have consistent viable counts. On average 
products from all manufacturing sites contained more than 109 CFU/ml viable counts, which is more 
than MSL. Product with extended storage period did not affect the viable cell densities and therefore 
the product quality in terms of viability, was not affected when the product extended for 2 more 
weeks. BBAN is the product consisting number of favourable characteristics of individual strains that 
are combined in a single preparation. Therefore, BBAN as a multi-species multi-strains product, with 
multiple probiotic effects combined together, may act synergistically to confer benefits to the host.   
5.3.4 Safety  
When selecting microbial strains to be used as probiotics, strains which possess a clear history of 
non-pathogenicity should be taken into account. Safety evaluation of the probiotics is implemented 
in different countries. GRAS status regulated by Food and Drug Administration (FDA) in USA and 
Qualified Presumption of Safety (QPS) status implemented by European Food Safety Authority 
(EFSA) in Europe are important references to monitor the safety of probiotics. It is generally 
recommended that the probiotic strain should possess either GRAS status or QPS status. BBAN 
comprises 4 LAB species and 3 yeast species and all of which possess QPS status which imply that 
these probiotic strains are safe to use in food product. GCMS studies indicated that BBAN did not 
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contain any undesirable metabolites which in some instances have been reported as the end 
product of fermentation.  
Throughout the study period product was tested for potential foodborne pathogens and test for 
bacterial pathogens was negative in all the occasions. High acidity of the product and metabolites 
produced by probiotic strains is effective and unfavourable against bacterial pathogens. However, 
detection of Rhodotorula species contamination in the product was effectively controlled during 
period of the study. Possible cause of the contamination source was detected and eliminated to 
ensure that this type of contamination would not be recurring in future. 
5.3.5 Metabolites 
Amongst different strategies against pathogenic and food spoilage organisms, metabolite production 
is regarded as an important probiotic mechanism (Gaggìa et al., 2010). Thus, probiotic product 
analysis for metabolic compounds have become an important in QA criteria. Furthermore, some 
undesirable metabolites produced as fermented end products have to be studied to makes sure 
product quality is maintained. Investigation of the BBAN for volatile metabolite analysis studied 
using SPME/GC-MS. Colorimetric enzymatic assays were used to evaluate lactic acid (non-volatile) 
and ethanol concentration in the BBAN samples. Lactic acid assay confirmed the major non-volatile 
metabolite detected in BBAN was lactic acid. Likewise, major volatile compounds detected in BBAN 
samples were grouped based on relative amounts, included organic acids (lactic acid, acetic acid and 
butyric  acid), alcohol (ethanol, phenylethyl alcohol and isoamyl alcohol), esters (ethyl acetate and 
ethyl butyrate) and phenol. Although different stages of production having different metabolites at 
varying quantity, generally they have been grouped into organic acids, alcohols, esters, carbonyl 
compounds, sulphur compounds and miscellaneous compound.  
Our results showed that important antimicrobial compounds such as lactic acid, ethanol and other 
alcoholic compounds, acetic acid, butyric acid, diacetyl, and etc. were identified in the BBAN. These 
metabolites play a key role in controlling gut pathogens and undesirable microorganisms.  
5.4 Model QA system 
Based on the results obtained from this study, we propose model QA system which includes testing 
parameters such as temperature, pH, viable counts of LAB and yeast, safety assessment and 
beneficial metabolites. Forms prepared for proposed QA system have been presented in Appendices 
E1-E4. 
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5.4.1 QA during Production stages 
BBAN product can be monitored at the end of each stages of production. Sample have to be tested 
for temperature, pH and viable counts. When tested samples at many stages of production meet the 
requirement mentioned in Table 5.2, then it is said that product at various stages satisfy the 
microbiological quality parameters. 
 
Table 5.2    QA specification for microbiological quality testing for various manufacturing stages 
 Stage 1 day 1 
   (Sugar fermentation) 
Stage 2 day 2 
(Molasses fermentation) 
Stage 3 day 3 
(Molasses fermentation) 
Sample ID  
 Yeast 
Date    
Temperature:  25 0C 25 0C 37 0C 
pH : 3.3 -4.0 4.0 - 4.5  3.5 - 4.0 
Viable counts:  9.0-10.0 CFU/ml 8.0-9.5 log CFU/ml 7.5 - 8.75 log CFU/ml 
  LAB 
Date    
Temperature:  37 0C 37 0C 37 0C 
pH :  3.8 - 4.5 4.0 - 4.5  4.0 - 4.5 
Viable counts:  7.0 -7.5 log CFU/ml 8.0 - 9.3 log CFU/ml 9.5 -10.5 log CFU/ml 
 
5.4.2 QA during storage  
QA of final product is important to deliver the expected beneficial effects to the host animal. Based 
on our research findings we have set the benchmark microbial counts of LAB and yeast at different 
storage days (Table 5.3). BBAN product tested for microbiological counts meet the benchmark viable 
count range at different storage days are considered that they satisfy the QA criteria. 
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 Table 5.3   QA specification for microbiological quality during storage 
Sample ID: 
Date: 
Storage 
days 
Viable count (log CFU/ml) 
 LAB                               Yeast  
pH Temperature  
Day1 9.00 -10.69  7.00-8.02  3.5 -4.0   
 
Room 
Temperature 
Day7 9.00 -10.99  5.5-6.10  3.5 -4.0  
Day14 9.00 -11.14  5.00-5.82  3.5 -4.0  
Day21 9.00 -11.07  5.00-5.55  3.5 -4.0  
Day28 9.00 -11.24  5.00-5.47  3.5 -4.0  
 
 
Furthermore, form BBQA03 explain product safety testing for potential foodborne pathogens 
(Staphylococcus species, E. coli, Coliform and Rhodotourula rubra) at different manufacturing stages 
and storage periods (Appendix E3). Test results show negative for these foodborne pathogens would 
assure the quality in terms of safety of the product. Likewise, form BBQA04 illustrates testing the 
product for metabolites (Ethanol, lactic acid, butyric acid, acetic acid and diacetyl) in the final 
product. Presence of these metabolites in the final product would ensure the quality assurance for 
beneficial metabolites. 
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Chapter 6 
Conclusions and recommendations 
6.1 Conclusions 
High quality animal feed ensures the quality of animal meat and by which it would improve 
consumer safety. In recent years, use of animal probiotic formulation have demonstrated prevention 
against zoonotic pathogens and infectious diseases by which improve the quality of animal meat. 
However, a high quality standard of the probiotic product should be met, in order to gain maximum 
health benefits from these products. BBAN is fresh animal probiotic formulation consisting of multi-
species and multi-strains of LAB and yeast strains in a molasses fermented media. 
In the current study we assessed the BBAN for important QA parameters including viable counts, 
metabolic compounds and safety assessment. In general, final product of the BBAN had more than 
recommended number of LAB viable counts irrespective of the storage days. However, yeast cell 
densities was higher in the first week of storage and started to decline towards the end of expiry 
date. Overall yeast counts in the product were just below the MSL.  
Metabolite profiling study revealed amounts and number of metabolites detected were different in 
products at many stages of production. However, detection of lactic acid, ethanol, organic acids, 
diacetyl and CO2 in the product suggested that the BBAN contained wider range of important 
antimicrobial compounds.  
Product safety assessment is important to assure the quality of the product. Investigation of the 
product for potential foodborne pathogens indicated that the product did not have any bacterial 
contamination throughout the study period. However, contamination with Rhodotorula rubra was 
reported for 2 batches. Product was recalled and factors conducive for disease contamination was 
identified and effectively eliminated. Constant viability of the product in association with production 
of antimicrobial metabolites confirmed the probiotic characteristics. Furthermore, safety assessment 
confirmed the product is safe to use it. Based on these studies proposed QA system was developed 
to monitor the BBAN products manufactured in future. Proposed QA system would make sure the 
products produced would be consistent, high quality BBAN products. 
In conclusion, BBAN satisfied the important QA parameters such as viability, metabolite compounds 
and safety assessment. Proposed QA system was developed to to produce consistent, high quality 
and safe BBAN. 
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6.2. Recommendations 
QA parameters we investigated confirmed that the BBAN: 
- had consistent viable counts throughout their shelf-life 
- was safe to use  
- Presence of desirable metabolites for probiotic effects. 
However, these parameters assure the quality of the product before it reaches the animal gut. 
Investigating performance of probiotics upon administration to the farm animals is also essential for 
QA criteria.in vitro and clinical assessment can be made to study following QA parameters. 
- acid and bile stability study 
- Ability to adhere and colonise in the gut. 
- Dose-response studies 
Yeast viable counts were slightly lower than MSL in the products. Plate count, culture-dependent 
method used in this study was like a stepping stone in this study and rapid culture-independent 
methods can be used to verify the yeast counts in the product. 
 Contamination during production caused by Rhodotorula rubra. Improvement in the production site 
in terms of hygienic and good practices would always make sure that consistent production of the 
product. Furthermore, Quality of the product can be maintained by constant implementation of 
standard operating procedure (SOP) in the facility. Plastic containers used in production of BBAN 
showed more affinity with these fungal organism. Replacing plastic containers with other types 
(Steel) of containers may reduce the chance of being contaminated. 
Unlike other probiotics, BBAN is not refrigerated but stored in room temperature. However, 
temperature control during production plays an important role for the microbial growth. Monthly 
variations in the product viable counts were observed and this may be due the effects of seasonal 
variations in the product. Setting up the facility in well protected and closed area may be helpful to 
avoid these variations.  
Product quality of different lots from same starter culture look inferior to normal standard products 
and this can be avoided rather product expiry day can be extended up to 6 weeks. 
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In general, BBAN contains 4 species of LAB and 3 species of yeast. However, colony counting did not 
differentiate which species was dominant in the product and species level counting was not 
undertaken. 
We analysed quantity of the metabolites in relative amount. However detecting true concentration 
by quantification method should be made to understand for validating the metabolite concentration 
in the BBAN. 
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Appendix A Log form of LAB and yeast population in different batches at many stages and during storage 
period 
A.1 LAB population 
 
130823 
L2 
130829 
L1 
130829 
L2 130906 
130926 
L1 
130926 
L2 131101 131108 131112 
140107 
L1 
140107 
L2 
140123 
L1 
140123 
L2 
140123 
L3 Ctrl1 
stage1 8.7993 9.0607 9.0607 5.8451 8.0414 8.0414 7.9542 5.8451 6.0569 6.1903 6.1903 8.2430 8.2430 8.2430 9.2455 
Stage2 8.9590 9.6990 9.6990 6.4314 6.8751 10.7324 8.1859 7.4146 9.5796 9.9445 9.9445 11.5119 11.5119 10.2253 9.1335 
stage3 9.5276 9.5263 9.5465 9.7723 10.8921 10.8808 9.2148 8.1614 10.4771 11.5623 11.8808 11.4594 11.5119 11.5119 11.4216 
day1 9.3636 9.6405 9.9542 9.9912 10.7160 10.8920 10.5798 8.3304 11.5132 11.7924 11.5888 11.5705 11.3838 11.4942 11.5752 
day7 9.4456 9.5366 10.7634 10.9243 10.7634 10.9031 11.7076 10.6128 11.0334 11.4942 11.4314 11.7292 11.3324 11.6474 11.5798 
day14 9.3766 10.7160 10.5315 10.5740 10.6758 10.8921 11.5682 11.4150 11.5051 11.7451 11.7482 11.9009 11.9325 11.1271 11.4502 
day21 10.3222 10.5119 10.5366 10.7356 10.5888 10.7324 11.3424 11.5623 11.3617 11.7126 11.8987 11.7482 11.4409 10.2201 11.2923 
day28 10.4914 10.6920 10.7634 10.9675 10.6684 10.8921 11.5563 11.5378 11.5051 11.9877 11.7574 11.4472 11.4048 11.1303 11.7435 
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A.2 Yeast population 
 
 
130823 
L2 
130829 
L1 
130829 
L2 130906 130926 131101 131102 131108 131112 131121 
140107 
L1 
140123 
L1 
140123 
L3 Ctrl 1 
stage1 9.6435 9.7076 9.7076 10.2041 10.1072 11.1072 11.0934 10.9243 9.6180 9.8573 10.8248 9.3201 9.3201 11.9877 
Stage 2 9.6902 9.8129 9.8129 9.3263 9.4150 9.7441 10.0732 9.8828 9.7378 10.8156 10.4393 9.6628 9.6628 11.4579 
stage3 9.4150 9.3598 8.0000 9.3909 8.9243 9.6085 9.7007 8.5378 7.6180 9.3617 8.7093 5.2900 8.3636 10.2355 
day1 9.5092 9.0170 8.7993 9.0294 7.2779 9.5416 8.2923 8.1614 7.5105 8.3424 7.1303 5.3979 7.0645 7.1367 
day7 6.0334 5.8751 6.7853 6.9542 4.9542 6.0414 7.2430 6.6335 7.1303 6.0492 4.9445 4.6128 6.0719 6.0682 
day14 5.6128 5.8195 5.9031 7.1139 4.9243 5.4624 5.5051 7.2304 6.4914 6.3222 5.5132 4.5051 6.1271 4.9731 
day21 5.3010 5.6021 6.1461 5.8513 4.8686 7.2201 5.8261 6.5798 5.6232 5.1614 4.5051 4.2553 5.7243 5.0531 
day28 6.0607 4.9294 5.1072 5.4472 4.8129 6.4914 5.4393 6.5315 6.2304 4.5441 5.2095 4.8921 6.1430 4.7076 
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Appendix B Volatile metabolites from BBAN (Control 1) at many stages of production isolated by the 
SPME/GC-MS 
Metabolite  CAS  KI  RT ST7 ST0 S3D3  S2 D3 L S2D3 Y S1D1L S1D1Y 
Compounds No published (mins) µg/l µg/l µg/l µg/l µg/l µg/l µg/l 
2-methyl-1-Pentene 763-29-1 - 3.54       10.5 6.1 9.4 5.8 
Dimethyl sulfide  75-18-3 844 4.05 7.1 9.1 7.9 0.0 27.9 0.0 0.0 
Ethyl formate 109-94-4 848 4.79 10.8 13.6 9.7 0.0 0.0 0.0 0.0 
Ethyl acetate  141-78-6 886 5.74 83.8 65.9 48.0 0.0 428.5 0.0 66.0 
Ethanol  64-17-5 929 6.84 1932.5 2250.3 1997.8 22.3 2696.9 0.0 1612.5 
2,5-dimethyl- furan  625-86-5 943 7.15 6.2 7.7 4.8 0.0 0.0 0.0 0.0 
Ethyl propanoate 105-37-3 950 7.28 0.0 0.0 0.0 0.0 11.7 0.0 0.0 
Diacetyl 431-03-8 977 7.75 0.0 0.0 0.0 0.0 18.6 13.8 0.0 
Ethyl butyrate 105-54-4 1028 9.50 567.4 591.5 511.1 0.0 50.3 0.0 0.0 
1-propanol 71-23-8 1040 9.59 0.0 0.0 0.0 0.0 20.4 0.0 0.0 
Isobutanol 78-83-1 1108 11.47 97.0 120.9 112.3 15.2 288.7 0.0 105.9 
isoamyl acetate 123-92-2 1117 12.29 7.7 6.7 5.7 0.0 21.3 0.0 0.0 
1-Butanol  71-36-3 1145 13.20 62.7 73.8 61.1 13.0 0.0 0.0 0.0 
isoamyl alcohol 123-51-3 1205 15.44 792.5 985.2 900.7 44.5 2558.1 0.0 881.2 
Ethyl hexanoate 123-66-0 1220 16.30 0.0 0.0 0.0 0.0 13.8 0.0 0.0 
isoamyl butyrate 106-27-4 1267 17.45 5.9 7.5 6.6 0.0 0.0 0.0 0.0 
cis-3-Hexenyl Acetate 3681-71-8 1308 19.27 - - - - - - - 
Ethyl octanoate 106-32-1 1436 23.29 0.0 0.0 0.0 0.0 54.5 0.0 10.0 
Acetic acid  64-19-7 1450 23.60 448.4 318.0 239.8 71.5 0.0 62.2 0.0 
2-ethyl-1-hexanol 104-76-7 1487 25.07 0.0 0.0 0.0 0.0 6.7 0.0 0.0 
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unknown - - 26.13 0.0 0.0 0.0 0.0 0.0 11.5 0.0 
2,3-Butanediol 513-85-9 1523 26.64 0.0 0.0 0.0 13.3 0.0 0.0 0.0 
1-Octanol 111-87-5 1553 27.23 0.0 0.0 0.0 0.0 7.9 0.0 0.0 
Butyric acid  107-92-6 1619 29.09 5401.1 6007.9 5380.4 2978.3 0.0 0.0 0.0 
Menthol 1490-04-6 1626 29.81 4.5 4.7 5.7 3.3 0.0 0.0 0.0 
unknown - - 32.68 7.0 0.0 0.0 29.5 7.3 0.0 0.0 
Phenyl butyrate 4346-18-3 - 33.36 8.6 59.8 77.4 6.5 0.0 0.0 0.0 
4-methylphenyl 
butyrate 14617-92-6 - 36.39 0.0 16.0 17.2 0.0 0.0 0.0 0.0 
Phenylethyl Alcohol  60-12-8 1925 37.32 15.8 16.0 17.8 0.0 81.2 0.0 10.9 
Phenyethyl butyrate 103-52-6 1930 38.76 7.6 7.5 6.3 0.0 0.0 0.0 0.0 
Phenol 108-95-2 1951 39.61 36.2 36.2 38.0 29.6 20.5 0.0 0.0 
  
 
Metabolites Internal Standard Unconfirmed ID 
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Appendix C Volatile metabolites from BBAN (Control 2) at many stages of production isolated by the 
SPME/GC-MS 
 
Metabolite Compounds CAS No KI  Retention Time St 0 S3D3 S2 D3 L  S2 D3 Y S1 D1 L S1 D1 Y 
    published (mins)  µg/l   µg/l   µg/l   µg/l   µg/l   µg/l  
2-methyl-1-Pentene 763-29-1 - 3.54 9.9 8.2 11.0 8.1 8.2 4.6 
Dimethyl sulfide  75-18-3 844 4.05 9.6 7.4 2.7 32.4 0.0 0.0 
Ethyl formate 109-94-4 848 4.79 9.1 10.6 0.0 0.0 0.0 0.0 
Ethyl acetate  141-78-6 886 5.74 125.1 73.4 0.0 615.3 0.0 87.0 
Ethanol  64-17-5 929 6.84 2304.5 2090.2 60.4 3364.9 0.0 1987.5 
2,5-dimethyl- furan  625-86-5 943 7.15 5.1 2.3 3.3 0.0 0.0 0.0 
Ethyl propanoate 105-37-3 950 7.28 0.5 0.4 0.0 20.1 0.0 0.8 
Diacetyl 431-03-8 977 7.75 3.7 4.4 10.4 16.3 18.9 33.0 
Ethyl butyrate 105-54-4 1028 9.50 369.4 207.9 0.0 156.1 0.0 0.0 
1-propanol 71-23-8 1040 9.59 0.0 0.0 0.0 30.4 0.0 8.4 
Isobutanol 78-83-1 1108 11.47 141.3 152.7 17.4 327.7 4.7 176.2 
isoamyl acetate 123-92-2 1117 12.29 10.7 8.7 0.6 26.8 0.5 44.5 
1-Butanol  71-36-3 1145 13.20 31.9 22.1 185.0 13.7 0.3 0.4 
isoamyl alcohol 123-51-3 1205 15.44 1075.9 927.3 62.0 3121.1 1.2 1288.3 
Ethyl hexanoate 123-66-0 1220 16.30 0.5 0.5 0.0 9.8 0.0 2.0 
isoamyl butyrate 106-27-4 1267 17.45 5.8 4.0 0.0 8.0 0.0 0.0 
cis-3-Hexenyl Acetate 3681-71-8 1308 19.27 - - - - - - 
Ethyl octanoate 106-32-1 1436 23.29 0.8 1.3 0.0 36.3 0.0 9.7 
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Acetic acid  64-19-7 1450 23.60 419.5 209.2 103.8 106.0 18.7 0.0 
2-ethyl-1-hexanol 104-76-7 1487 25.07 5.7 6.3 5.8 6.7 3.8 5.0 
unknown - - 26.13 2.4 1.9 1.8 1.7 2.4 1.6 
2,3-Butanediol 513-85-9 1523 26.64 5.6 2.7 4.2 3.0 0.0 0.0 
1-Octanol 111-87-5 1553 27.23 9.0 8.8 7.3 8.3 3.6 4.3 
Butyric acid  107-92-6 1619 29.09 4626.0 3151.8 4154.6 932.5 0.0 0.0 
Menthol 1490-04-6 1626 29.81 2.7 3.5 5.2 0.0 0.0 0.0 
unknown - - 32.68 6.9 7.7 6.2 7.1 4.2 5.1 
Phenyl butyrate 4346-18-3 - 33.36 15.8 15.5 12.0 0.0 0.0 0.0 
4-methylphenyl butyrate 14617-92-6 - 36.39 5.9 4.8 5.4 0.0 0.0 0.0 
Phenylethyl Alcohol  60-12-8 1925 37.32 18.6 15.1 1.3 93.8 0.0 26.4 
Phenyethyl butyrate 103-52-6 1930 38.76 2.2 0.0 2.3 3.0 0.0 0.0 
Phenol 108-95-2 1951 39.61 19.9 15.5 53.2 31.0 0.0 0.0 
 
 
Metabolites Internal Standard Unconfirmed ID 
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Appendix D Total volatile compounds identified by the SPME/GC-
MS in BBAN (similarity match % - Control 2 ST 28)  
  
Metabolite Compounds CAS No 
KI 
Published 
Retention 
Time (min) 
Similarity 
match % 
 
Dimethyl sulfide  75-18-3 844 4.04 
98  
Ethyl formate 109-94-4 848 4.77 
99  
Ethyl acetate  141-78-6 886 5.72 
97  
Ethanol  64-17-5 929 6.84 
96  
2,5-dimethyl- furan  625-86-5 943 7.13 
98  
Diacetyl 431-03-8 977 7.75 
89  
ethyl butanoate 105-54-4 1028 9.49 
98  
butyl acetate 123-86-4 1105 10.58 
88  
2-methyl- 1-propanol 78-83-1 1108 11.60 
99  
isoamyl acetate 123-92-2 1117 12.20 
98  
(3E)-3-penten-2-one 3102-33-8 1128 12.42 
95  
2-pentanol 6032-29-7 1130 12.46 
95  
1-Butanol  71-36-3 1145 13.31 
99  
Isobutyl butyrate 539-90-2 1152 13.49 
98  
isoamyl alcohol 123-51-3 1205 15.48 
98  
Ethyl hexanoate 123-66-0 1220 16.20 
94  
isoamyl butyrate 106-27-4 1267 17.37 
99  
cis-3-Hexenyl Acetate 3681-71-8 1308 19.26 
96  
1-hexanol 111-27-3 1360 20.49 
96  
3-octanol 589-98-0 1406 21.88 
91  
Ethyl octanoate 106-32-1 1436 23.24 
89  
Acetic acid  64-19-7 1450 23.56 
98  
1-Octanol 111-87-5 1553 27.32 
97  
Butanoic acid  107-92-6 1619 29.03 
97  
Menthol 1490-04-6 1626 29.77 
97  
meththionol 505-10-2 1738 31.93 
92  
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Methyl salicylate 119-36-8 1786 33.65 
92  
Benzyl alcohol 100-51-6 1865 36.39 
97  
Phenylethyl Alcohol  60-12-8 1925 37.29 
98  
Phenol 108-95-2 1951 39.57 
97  
p-Ethylguaiacol 2785-89-9 2048 40.32 
90  
gamma-nonalactone 104-61-0 2024 40.34 
95  
3p-Cresol 106-44-5 2077 41.48 
97  
Eugenol  97-53-0 2161 43.62 
93  
4-ethyl-phenol 123-07-9 2195 43.72 
97  
(Z)-isoeugenol 5912-86-7 2298 47.68 
92  
 
 
 
 
 
 
 
 
 
  
 
 
80 
Appendix E Viable counts of LAB and yeast during stages of 
production and storage 
E.1 BBQA1 Viable counts of LAB and yeast during stages of production 
 Stage 1 day 1 
   (Sugar fermentation) 
Stage 2 day 2 
 
(Molasses fermentation) 
Stage 3 day 3 
(Molasses fermentation) 
Sample ID  
 Yeast 
Date    
Temperature:     
pH :    
Viable counts:     
  LAB 
Date    
Temperature:     
pH :     
Viable counts:     
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 E.2 BBQA2 Viable counts of LAB and yeast during storage  
Sample ID: 
Date: 
Storage 
days 
Viable count (log CFU/ml) 
 LAB                               Yeast  
pH Temperature  
Day1     
 
 Day7    
Day14    
Day21    
Day28    
 
 
 
E.3 BBQA03: Product safety testing and results 
  
Date 
tested 
Production 
Stage 
Sample 
ID 
pH To Staphylococcus 
species 
E. coli  Coliform  Rhodotourula 
rubra 
 Stage 1 day 1        
 Stage 2 day 2        
 Stage 3 day 3        
 Storage day 7        
 Storage day 14        
 Storage day 28        
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 E.4 BBQA03: Product metabolites testing and results 
 
Date 
tested  
Production 
Stage 
Sample 
ID 
pH To Ethanol  Lactic 
acid  
Butyric 
acid 
Acetic 
acid  
Diacetyl 
 Stage 3 day 3         
 Storage day 7         
 Storage day 14         
 Storage day 28         
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